

Market snapshot

آلت]

Equities - India	Close	Chg .%	CYTD.%	
Sensex	38,024	0.7	5.4	
Nifty-50	11,427	0.7	5.2	
Nifty-M 100	17,863	0.6	-0.1	
Equities-Global	Close	Chg .%	CYTD.%	
S&P 500	2,822	0.5	12.6	
Nasdaq	7,689	0.8	15.9	
FTSE 100	7,228	0.6	7.4	
DAX	11,686	0.8	10.7	
Hang Seng	11,508	0.5	13.7	
Nikkei 225	21,451	0.8	7.2	
Commodities	Close	Chg .%	CYTD.%	
Brent (US\$/Bbl)	67	-0.4	25.1	
Gold (\$/OZ)	1,302	0.5	1.6	
Cu (US\$/MT)	6,446	0.5	8.4	
Almn (US\$/MT)	1,875	-0.1	0.6	
Currency	Close	Chg .%	CYTD.%	
USD/INR	69.1	-0.4	-1.0	
USD/EUR	1.1	0.2	-1.2	
USD/JPY	111.5	-0.2	1.6	
YIELD (%)	Close	1MChg	CYTDchg	
10 Yrs G-Sec	7.3	-0.02	0.0	
10 Yrs AAA Corp	8.7	-0.02	0.2	
Flows (USD b)	15-Mar	MTD	CYTD	
FIIs	0.62	3.06	4.51	
DIIs	-0.31	-1.60	-1.07	
Volumes (INRb)	15-Mar	MTD*	CYTD*	
Cash	507	404	344	
F&O	8,830	10,403	9,597	

Today's top research idea

Automobiles: Auto demand in Maharashtra weak across segments...

... impacted by weak farm sentiments; inventory at record levels

- To understand the on-ground demand environment across segments in automobiles, we interacted with participants from major urban and rural markets in Maharashtra. Auto demand is weak in the key markets of Maharashtra led by negative farm sentiments due to a steep 30-40% decline in wholesale crop prices this season. The drought-like situation in key rural markets, worsened the situation.
- In 2Ws, negative farm sentiment and increased insurance cost resulted in it being the worst hit; sales declined 15-20% in FY19. PV demand trend was mixed across regions; enquiries-to-sales conversion was weak for existing models, while new product launches attracted footfalls.
- Tractor demand was weak led by adverse farm sentiments and low subsidy release by the government. With this backdrop, our top auto picks are MSIL and MSS among large caps, and EXID and ENDU among midcaps.

Research covered

Ð

ſ

Cos/Sector	Key Highlights
Auto (Ground Reality)	Demand in Maharashtra weak across segments
Hindustan Unilever	Short-term blip in demand; Investment case remains strong
Lupin	Somerset site classified as OAI, regulatory concerns rising
Automobiles	CV ecosystem preparing for regulatory/tech changes
EcoScope	Trade deficit at 17-month lowest in February 2019
Healthcare Monthly	Slight pick-up in volumes; Price growth remains the key
Cement	Price hikes taken in Feb'19 moderate in Mar'19

Piping hot news


Airtel finds Dish appetising, signals interest for merger

It's not just telecom, but also TV distribution space where Sunil Bharti Mittal has decided to give a tough fight to Mukesh Ambani's Reliance Jio.

Note: *Average

ⓓ

Chart of the Day: Cement – Price hikes taken in Feb'19 moderate in Mar'19



All-India prices increased 3% QoQ in 4QFY19



Research Team (Gautam.Duggad@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

1

L&T set to seal Mindtree deal with Café Coffee Day founder VG Siddhartha

Larsen & Toubro (L&T) is planning to sign a deal with Café Coffee Day founder VG Siddhartha to buy his 21% stake in Mindtree and launch an open offer for an additional 31% stake in the IT company, probably as early as Monday evening...

In the news today

Kindly click on textbox for the detailed news link

2

Blue Star defers plan to set up unit at Sri City

Air-conditioning and refrigeration major Blue Star Ltd. has deferred its plan to set up a greenfield project in Sri City by two years due to a slump in demand in recent months, said its joint managing director B. Thiagarajan. "Last summer was bad for the industry as a whole, and also for us in terms of volume as some of the States witnessed rains. Besides, the industry also had to face issues such as increase in commodity prices, customs duty hike, foreign exchange movement and the NBFC crisis," he said...

3

SBI moves High Court for 2.8% in UBL

State Bank of India (SBI), one of the lead lenders to Vijay Mallya's businesses, has moved the Karnataka High Court to seek rights over a 2.8% stake, worth Rs 1,025 crore, in beer maker United Breweries Ltd (UBL) held by a court-appointed liquidator...

4

IL&FS to receive first set of bids under asset monetization process on Monday

Cash-strapped IL&FS Group will receive first set of bids under asset monetization process on Monday as part of resolution process, according to sources. The company's board will later consider bids for Rs 8,000 crore renewable energy business that was put on the block in November 2018...

6

Wadhawan Global sells stake in education loan arm to Warburg

Wadhawan Global Capital (WGC) has decided to sell its entire stake of 49.04% in its education finance subsidiary, Avanse, to an affiliate of private equity firm Warburg Pincus Group, while Dewan Housing Finance Corporation Ltd., a group company, will also sell its 30.63% stake...

7

Rupee payment for Venezuelan oil under consideration

India is considering Venezuela's proposal to use rupee for trade payments to protect the current oil import from the South American nation facing hardening US sanctions...

5

Steel makers seek ban on Iran imports

The Indian Steel Association (ISA), which represents top local makers of the alloy, has urged New Delhi to take immediate steps to ban imports from Iran after a near five-fold increase in shipments that might be traced back to the Persian Gulf nation...

15 March 2019 Sector: Automobiles



Ground Reality

Auto demand in Maharashtra weak across segments...

...impacted by weak farm sentiments; inventory at record levels

On a visit to major urban and rural markets in Maharashtra, we interacted with key participants from the automotive eco-system to understand the on-ground demand environment across segments. Auto demand was impacted due to a steep decline of 30-40% in wholesale prices of key crops this season, while the drought-like situation in key rural markets further worsened demand. In the present environment, we believe that an upsurge in demand will hinge on farm sentiment revival in these regions. Key takeaways:

- Auto demand was weak in the key markets of Maharashtra led by negative farm sentiments. Weak demand was not only led by steep decline of 30-40% in wholesale prices of key crops this season, but also due to the drought-like situation in key rural markets (Ahmednagar).
- 2W retail was the worst hit among auto segments, declining 15-20% in FY19. Negative farm sentiments along with increased insurance cost resulted in weak enquiries.
- Increasing preference for scooters has been noticed in the rural areas (35-40% share), led by better road infrastructure. Also, rural families who already own a motorcycle usually consider buying a scooter as their second option.
- Royal Enfield's retail continues to decline across regions, impacted by (a) postponement of purchase by customers in key rural areas, (b) significant increase in purchase cost led by mandatory insurance and regulations, and (c) competition from Jawa.
- PV demand trend remains mixed across regions with enquiries-to-sales conversion continuing to remain weak for the existing models, while new product launches attracted footfalls.
- Tractor demand was weak led by adverse farm sentiments and low subsidy release by the government.

Negative farm sentiment due to ~30-35% drop in farm realizations and increasing cost burdens

- Auto demand was weak in the key markets of Maharashtra led by negative farm sentiment due to a steep decline of 30-40% in wholesale crop prices this season and due to a drought-like situation in key rural markets.
- Price of grapes in Nashik region's wholesale markets plummeted by ~40-45% in the domestic market to INR30/kg and by ~30-35% in the export market to INR45/kg.
- Our interaction with a farmer involved in onion farming indicates ~50% decrease in realizations, as current cost
 of production stands at an average INR4-4.5/kg v/s current realizable value of an average INR1.5-2/kg.
- Further, increased cost of animal fodder (imported from nearby states) is an additional financial burden.

2W retails worst hit with record non-festive inventory

- With negative farm sentiments prevailing, auto retail across segments is witnessing decline of 15-20% in FY19.
- The overall 2W segment is currently witnessing decline of 15-20% in sales, except for the 125cc scooters, which is an upgrade option to the existing 110cc scooters. Negative farm sentiments and increased insurance cost resulted in weak sales enquiries.
- Our interaction with leading channel partners in drought-hit regions reveal that customers will continue postponing buying decisions till the next monsoon season, but festive demand during the upcoming festival of 'Gudi Padwa' (12-15% of yearly sales) could be the only saving grace.
- Weak sales enquiries have led to record inventory across OEMs. We note that channel partners of HMCL hold the highest inventory of 9-10 weeks, while TVSL and BJAUT's inventory is in the 6-7 weeks range.
- Consequently, as a support to channel partners, HMCL would bear interest cost on the excess inventory (beyond 5-6 weeks), effective Jan'19.

Scooterization gathers pace, while entry/executive motorcycle still preferred in rural areas

- Further, there is increasing preference for scooters in rural areas (~35-40%), led by better road infrastructure.
 Also, rural families who already own a motorcycle usually consider buying a scooter as their second option.
- While Activa continues to enjoy strong brand preference within rural areas, its share in urban markets is stagnating as customers are considering higher 125cc brands like Suzuki Access and TVS Ntorq.

Aggressive financing and consumer offers helping Bajaj Auto's retails

- Amongst the mass 2W market, BJAUT offers the highest incentives like free owner damage insurance and free five-year warranty for even the top-selling models like Platina 100 ES, CT-100 alloy KS, and CT-100 alloy ES. Further, it has similar offers in Pulsar 180, Pulsar 200 NS, and Pulsar 200 NS ABS.
- Other OEMs, such as HMCL, HMSI and TVSL, are not extending any type of incentives, offers or schemes.
- In a bid to gain market share, we found BJAUT more aggressive in terms of vehicle financing (up to 90% LTV).
 Bajaj Finance's share of BJAUT 2W volumes has increased to 52% in 3QFY19 (v/s average of 33-35%).

Royal Enfield's retails continue to decline across channel partners and regions

- Royal Enfield sales continued declining significantly by up to 20% across the major regions impacted by (a) postponement of purchase by customers in key rural areas, (b) significant increase in purchase cost led by mandatory insurance & regulations and c) competition from Jawa.
- Our interaction with key channel partners indicate significant decline (from peaks) of ~60% in Pune, ~30% in Nashik and ~30% in Ahmednagar regions.
- This has led to a significant increase in inventories across dealerships at 30-35 days (v/s 20-25 days earlier).

New product launch in PVs bring back footfalls, inventory level back to higher levels


- The PV demand trend remains mixed across regions with enquiries-to-sales conversion continuing to remain weak for existing models.
- However, new product launches such as New Ertiga, New WagonR, XUV3OO, Marazzo and Harrier should help bring footfalls to the showrooms.
- MSIL continues to outperform peers with healthy waiting period of an average 22-24 weeks for the New Ertiga, while for the new WagonR, waiting period stands at an average of 4-6 weeks. We note that 60-65% of the WagonR booked is for higher trims and 1.2liter engine, attracting customers from Grand i10 and its own Celerio.
- Post launch of the new Ertiga, MM's Marazzo witnessed significant decline in enquiries/sales led by significant price difference of INR1-1.2L, providing better value options to attract the fleet segment.
- Perception of TTMT cars is changing rapidly among clients, reflected in a steady demand for Tiago and the compact SUV Nexon. However, the newly launched Harrier is yet to gain traction as customers are sticking to the existing premium brands such as Jeep Compass and XUV500.
- The average inventory level for MSIL stands at 30-35 days and for PVs from M&M, it remains higher at ~40-45 days.

Tractor demand weak on lower subsidies from the government

- Nashik and Ahmednagar markets are dominated by the mid-range tractor segment (35-40 HP) with 50% share; ~60-70% of the application here is related to agriculture and allied activities, while balance are used in other infrastructure activities.
- On the other hand, lower HP tractors (20-30 HP) are used for grape and orchard farming activities.
- While demand for tractors has declined by 8-10% in YTDFY19, OEMs like Escorts are gaining share from M&M, which has ~30% market share in the Nashik region (v/s 34% earlier).
- The decline in demand is partly attributed to a significantly low tractor purchase subsidy by the government (only 30-35% of applications were granted subsidy).

Valuation and view

- 2W demand should grow at 7.5% CAGR in FY19-21 led by pre-buying ahead of BS6 norms. Ownership costs will increase ~16-18% post BS6 norms, which will impact demand in FY21. We expect faster growth in scooters and premium motorcycle segment led by value migration and up-trading from the executive segment.
- We prefer 4Ws over 2Ws and CVs due to their stronger volume growth and stable competitive environment.
- Our top picks in autos are MSIL and MSS among large caps, and EXID and ENDU among midcaps.
- In 2Ws, we have a Buy rating on BJAUT and EIM, and a Neutral rating on HMCL and TVSL.



Source: MOFSL



S&P CNX

11,427

Hindustan Unilever

BSE SENSEX 38,024



Hindustan Unilever Limited

Stock Info

Bloomberg	HUVR IN
Equity Shares (m)	2,164
M.Cap.(INRb)/(USDb)	3677 / 53.2
52-Week Range (INR)	1871 / 1282
1, 6, 12 Rel. Per (%)	-11/4/18
12M Avg Val (INR M)	2433
Free float (%)	32.8

Financials Snapshot (INR b)

Y/E Mar	2019E	2020E	2021E
Net Sales	382.4	436.2	498.7
EBITDA	86.6	103.0	122.5
Net Profit	62.3	74.2	88.5
EPS (INR)	28.8	34.3	40.9
EPS Growth (%)	17.5	19.1	19.3
BV/Share (INR)	34.1	33.7	31.4
P/E (x)	59.0	49.6	41.6
P/BV (x)	49.8	50.5	54.0
RoE (%)	86.1	101.2	125.6
RoCE (%)	121.7	144.9	179.8

Shareholding pattern (%)

As On	Dec-18	Sep-18	Dec-17
Promoter	67.2	67.2	67.2
DII	7.4	7.3	6.3
FII	12.0	12.1	12.9
Others	13.4	13.4	13.6

FII Includes depository receipts

Stock Performance (1-year)



CMP: INR1,699 TP: INR2,125 (+25%)

Buy

Short-term blip in demand; Investment case remains strong

We spoke to the management of Hindustan Unilever (HUL) for an update on the overall market conditions. Key takeaways:

- A small short-term blip was seen in 4QFY19 demand. But, we had already built in 8% volume growth for 4QFY19 v/s double-digit growth of the preceding five quarters.
- Measures announced in the budget are expected to benefit demand from 1QFY20 onwards. We see no immediate threat to our FY20 forecast of 7.5% volume growth.
- We believe HUVR will continue to outperform peers over the medium term.
- Material cost outlook remains benign, ad spends & promotion intensity have not picked up erratically and cost savings continue at the targeted pace.
 - Valuation & View: There is no change to our forecasts. We expect its high multiples to sustain (a) on combination of continued healthy volume growth v/s peers, (b) on better earnings growth v/s its own past earnings, (c) because of the company's bestin-breed return ratios, and (d) due to synergies from the GSKCH acquisition from FY21 (we are not building in benefit from the acquisition yet in our numbers). We maintain BUY rating on the stock with a target price of INR2,125, target multiple of 52x FY2021 EPS (which is ~15% premium to 3-year average due to significantly improving business fundamentals).

Some moderation seen in overall pace of growth in the FMCG market

- Our conversation with the HUL management indicated that there is a bit of relative slowdown in 4QFY19 demand compared to the preceding five quarters, which had witnessed double-digit volume growth.
- Slight slowdown was witnessed across rural and urban. Rural growth remains well ahead of urban; but rural growth over urban has declined a tad, to less than 1.3x urban growth seen in the previous quarter.
- Therefore, we believe that HUVR is unlikely to report double-digit volume growth; but, we were already building in 8% volume growth for 4QFY19 in our forecasts.
- Importantly, there appears to be no concern over the medium-to long-term demand. With benefits on the demand front due to the budget coming through in FY20, we maintain our 7.5% volume growth forecasts for FY20/FY21.
- It is pertinent to note that HUL has been a huge outperformer on volumes compared to peers, despite being multiple times larger. (See exhibit no. 1)
 We expect HUVR's volumes, topline and earnings to continue outperforming
 - its peers, as well as its own past record, led by:
 - It's rapidly improving adaptability to market requirements exemplified by its 'Winning in Many Indias' (WIMI) strategy.
 - Its recognition and strong execution on Naturals as a key sub-segment across categories.

Continuous strong trend towards premiumization.

Extensive plans to employ technology and creating further entry barriers. Continued increase in efficiency levels leading to cost savings.

- The temporary blip in 4QFY19 demand may affect other relatively smaller-sized consumer companies more.
- Material cost outlook continues to remain benign, which is great for HUVR and other players from a 4QFY19 perspective, compared to the pressures witnessed in 3QFY19.
- Ad spend intensity in the sector has not changed. New launches and variants launched recently are doing well for HUVR.

Valuation and view

- There is no change to our forecasts. A combination of continued healthy volume growth v/s peers and better earnings growth compared to its own past record, aligned with best-in-breed return ratios, and synergies from the GSKCH acquisition from FY21 onwards (we are not building in benefit from the acquisition yet in our numbers), will lead to sustained high multiples.
- We maintain BUY rating on the stock with a target price of INR2,125, target multiple of 52x FY2021 EPS (~15% premium to 3-year average due to significantly improving business fundamentals).

		-						-								
Quarterly volume growth (%)	4Q15	1Q16	2Q16	3Q16	4Q16	1Q17	2Q17	3Q17	4Q17	1Q18	2Q18	3Q18	4Q18	1Q19	2Q19	3Q19
HUVR (Domestic)	6.0	6.0	7.0	6.0	4.0	4.0	(1.0)	(4.0)	4.0	0.0	4.0	11.0	11.0	12.0	10.0	10.0
Marico (Domestic)	3.0	6.0	5.5	10.5	8.4	8.0	3.0	(4.0)	10.0	(9.0)	8.0	9.4	1.0	12.4	6.0	5.0
Dabur (Domestic FMCG)	8.1	8.1	5.5	(2.5)	7.0	4.1	4.5	(5.0)	2.4	(4.4)	7.2	13.0	7.7	21.0	8.1	12.4
Emami (Domestic)	12.0	15.0	13.5	9.3	18.0	18.0	11.0	0.2	(1.5)	(18.0)	10.0	6.0	8.0	18.0	(4.0)	3.5

Source: Company, MOFSL

Lupin





LPC IN
452
355.3 / 5.1
986 / 724
-9/-19/-12
2150
53.0

Financials & Valuations (INR b)

2019E	2020E	2021E
161.4	180.4	202.1
25.4	35.7	42.0
11.7	17.3	21.7
25.9	38.3	48.1
-18.9	47.8	25.5
306.9	334.7	372.2
8.5	11.9	13.6
5.2	9.0	10.3
32.5	22.0	17.5
2.7	2.5	2.3
	161.4 25.4 11.7 25.9 -18.9 306.9 8.5 5.2 32.5	25.4 35.7 11.7 17.3 25.9 38.3 -18.9 47.8 306.9 334.7 8.5 11.9 5.2 9.0 32.5 22.0

CMP: INR786 TP: INR1,000 (+27%)

Buy

Somerset site classified as OAI, regulatory concerns rising

- The USFDA has classified its inspection in Dec'18 at Lupin's (LPC) Somerset formulation facility as Official Action Indicated (OAI). This is the second OIA classification been issued to LPC over the past few days (Mandideep and now Somerset). Subsequently, there have been concerns about the USFDA taking further regulatory actions and withholding ANDA approvals from these sites.
 Nevertheless, we maintain our estimates for LPC, noting that the OAI status does not stop it from selling products in the US market.
- We expect earnings CAGR of 36% over FY19-21 on the back of a low base of FY19, new launches in the US market and the sustained outperformance in the domestic branded formulation/Japan markets. We have a Buy rating on the stock with a price target of INR1,000 (based on 20x 12-month forward earnings). Regulatory developments at Somerset/Mandideep and the sites under the warning letter will the key monitorables over the near term.

USFDA changes inspection status at Somerset/Mandideep to OAI: The USFDA had inspected the company's Somerset facility in Dec'18 and issued form 483. Based on the observations and the subsequent CAPA (Corrective and Preventive Action), the USFDA has changed the status of the inspection to OAI. LPC is in process of sending further updates on CAPA to USFDA.

The Somerset site was part of the Gavis acquisition done in 2015. Around 40 ANDAs are pending for approval from this site (v/s 66 at the time of acquisition). Incremental sales from the Gavis acquisition were ~USD96m, which has now increased to ~USD130m (about 17% of 12M trailing US sales) led by new launches and price erosion in the base business.

LPC has also received OAI status at Mandideep (unit 1) post the USFDA inspection in Dec'18. No ANDAs are pending for approval from this site. The share from this site would be less than 5% of US sales.

For LPC, a total of 154 ANDAs are pending for approval.

Regulatory risk increasing: The OAI status at Somerset/Mandideep and the warning letter at Indore/Goa increase the regulatory risk for LPC.

Valuation view: We maintain our estimates as the change in status to OAI does not stop LPC from selling products in the US market. We expect healthy traction from new launches in the US market and sustained outperformance in the domestic formulation and Japanese markets. We value LPC at 20x 12M forward earnings and arrive at a TP of INR1,000. We maintain our **Buy** rating. Regulatory developments at Somerset/Mandideep and the sites under warning letters will the key monitorables over the near term.

Automobiles



CV ecosystem preparing for regulatory/tech changes

LCVs might be worst impacted under BS6 due to steep price increases

We attended the ET Auto CV and Logistics Conclave 2019 at Pune, where all the key stakeholders of the Indian CV industry (CV players, components suppliers, fleet operators, and financiers, among others) discussed the forthcoming opportunities and challenges for the industry. The fast-changing regulatory and technological landscape will have a strong influence on the CV industry over the next five years. While the CV industry is well prepared for BS6 transition, LCVs are staring at demand disruption post BS6 due to pressure from cost increases.

GST, rapid infra development, ecommerce – the change agents

- Implementation of GST has shifted the focus from optimization of sales tax to optimization of logistic costs. This has been enabled by rapid development of road infrastructure, resulting in creation of new hubs.
- Ashok Leyland (AL) has become more rational about logistics, with the number of regional sales offices (RSOs) now down to 5 from 26 before GST implementation.
- Post GST, 40% of states have removed sales tax-related check-posts. The other states are slow on this but should follow suit.
- The emergence of ecommerce is bringing about paradigm changes in the logistics industry with a need of segment-specific vehicles and technology to improve efficiencies.
- The aforementioned factors are leading to segmental shifts within the M&HCV and LCV industries and improving fleet utilization. Distance travelled per day has increased by 10% post GST to 270-280km from 240km earlier. Further improvement in toll collection efficiencies and practices at RTO check-posts could increase this number to 400-450km/day (v/s 800km/day in the US and 600km/day in the EU).

Regulatory/technological changes can improve efficiencies

- The CV industry has undergone several major regulatory changes over the last few years, such as mandatory ABS, BS4 compliance, mandatory AC/blower, vehicle tracking devices (for buses) and an increase in axle load.
- While BS6 transition is set for Apr'20, there are several regulatory changes under deliberation, viz., (a) mandatory scrapping of over 20 years old trucks and (b) new body building code.
- On the other hand, technology has taken center stage in the CV industry, with an increase in the use of electronics, sensors and improved connectivity. Technology is enabling remote/preventive diagnostics, fleet management, driver monitoring, fuel efficiency improvement, digital distribution of parts, etc.
- While currently only 10-15% M&HCVs are fitted with telematics, the increasing role of aggregators and ecommerce would drive faster adoption of technology in the CV industry. Adoption of technology in LCVs/SCV is slower but should improve from 2020.

 By Apr'20, regulatory and safety norms (except dynamic collusion norms) in India would be closer to EU standards.

LCVs staring at substantial price increases, demand weakness post BS6...

- Under BS6, the LCV/SCV segments would see substantial cost increases much higher than the 10-12% increase expected in the M&HCV segment. Also, certain segments (like sub-1 ton segment) may face existential crisis, which would force OEMs to look at alternatives like CNG and electric vehicles.
- Considering the magnitude of price increase, OEMs might think of taking price hikes in a staggered manner.
- Hence, the demand environment for LCV/SCVs post BS6 may turn very challenging. AL expects the LCV industry volumes to grow from ~625k units annually now to 725-750k units in four years, with FY21 witnessing a decline of 20-30%.
- For LCVs, constrained finance (since this segment is dominated by NBFCs) and an increase in interest rates (by 1-1.5%) could also impact demand, although NBFC participants expect interest rates to moderate in a few quarters.

...though long-term growth opportunity is attractive

- LCV segment growth would be led by increased consumption and newer applications (garbage truck, tippers, tankers, etc.).
- Globally, 75% of CV volumes come from LCVs, as against ~62% in India. Based on AL's estimate, LCVs would contribute ~70% to CV industry volumes in the next four years.
- Customer centricity at OEM level is a big change in the LCV industry, leading to a shift from standard products to manufacture of products based on customer needs. The trend of 'electronification' (like seen in PVs) is also expected to accelerate in LCVs.
- Shift toward rural areas is also visible. A significant level of LCV purchases are now happening in semi-urban and rural areas.

Spares & service business to witness further formalization under BS6

- In the BS4 era, the number of trucks coming back to authorized service centers is increasing. With BS6, this trend will only grow due to the rise in electronic content and usage of complex technologies.
- A large part of dealer bottom line at service centers comes from accidentrelated work (80% of profits, 30% of manpower) and the balance from maintenance work.
- According to Daimler India Commercial Vehicle (DICV) estimates, aftermarket opportunities will be reduced by 40% in EVs. However, accident-related repairing revenues will not get impacted.

Alternative fuel usage to go up over long term

- DICV believes that, in the long run, LCVs will shift toward EVs, and M&HCVs toward hydrogen fuel.
- Industry has to be prepared to handle the multiple propulsion system.
- While natural gas usage will go up, it is expected to be a fringe fuel in longdistance travel. As a result, there is not adequate investment happening on the engine side for natural gas from OEMs.

Other insights

- Driver availability is a concern, as 28% of trucks are remaining idle due to driver shortage.
- Improper loading and unloading schedule is leading to loss of ~8% of revenues for fleet operators.
- Toll is now third highest cost (~15% of total cost).
- Post recent order of 1,000 e-buses, there is another order of 2,000 e-buses in the pipeline.

Valuation and view

- Domestic CV industry is witnessing cycles within a cycle led by regulatory changes (axle load norms), financing issues and the upcoming election. We estimate CV industry volumes to remain muted for another quarter or so, and then recover from 2QFY20. However, 1HFY21 will again witness a downcycle post BS6 implementation (longer downcycle for LCVs).
- Hence, we estimate a muted CV demand CAGR of 0.8% over FY19-21 (impacted by ~ 13% decline in FY21). However, mandatory scrappage of >20 years old trucks, if implemented from Apr'20, will more than offset any impact of pre-buy in FY21 (not factored in our estimates).
- However, valuations are also reflecting for the same at ~20% discount to the LPA. RoCEs are likely to remain stable over FY19-21.
- AL is our preferred pick in the CV segment as it is the only pure play on the CV industry. AL has shifted its focus toward expanding and creating new revenue and profit pools, which is helping it to reduce volatility in its business. We factor in revenue/EBITDA/PAT CAGR of 9%/-0.2%/-8% over FY19-21. Maintain **Buy** with a TP of INR110 (8x Mar'21 EV/EBITDA + INR13/share for NBFC).

	СМР	Rating	ТР	P/E	(x)	EV/EBI	TDA (x)	RoE	(%)	Div Yi	eld (%)	EPS CAGR (%)
	(INR)		(INR)	FY19E	FY20E	FY19E	FY20E	FY19E	FY20E	FY19E	FY20E	FY18-20E
Auto OEM's												
Bajaj Auto	3,022	Buy	3,045	19.0	17.1	13.8	11.6	22.8	22.8	2.0	2.3	8.2
Hero MotoCorp	2,739	Neutral	2,928	15.9	15.1	9.3	8.7	28.1	27.7	3.8	4.2	-1.1
TVS Motor	493	Neutral	576	32.4	22.4	16.3	12.0	23.1	27.8	0.8	1.0	25.6
M&M	693	Buy	841	16.7	14.6	12.8	10.7	14.5	14.1	1.4	1.4	7.5
Maruti Suzuki	7,092	Buy	8,131	29.0	24.3	16.0	13.7	16.3	17.4	1.4	1.8	4.6
Tata Motors	180	Neutral	166	-41.4	10.5	4.3	3.3	-1.8	8.5	0.2	0.2	-13.3
Ashok Leyland	94	Buy	110	13.3	12.8	8.6	6.7	26.7	24.1	2.7	2.8	10.9
Eicher Motors	22,632	Buy	23,960	26.5	22.6	20.8	18.4	29.5	27.7	0.5	0.5	11.8
Escorts	799	Neutral	754	14.6	13.2	11.6	10.2	20.0	18.8	0.6	0.6	23.7
Auto Ancillaries												
Bharat Forge	534	Buy	568	22.5	19.5	13.0	11.3	21.9	21.5	1.0	1.2	21.8
Exide Industries	229	Buy	280	25.6	21.1	13.7	11.4	12.7	14.1	1.1	1.4	15.1
Amara Raja Batteries	746	Buy	855	26.1	20.8	13.2	10.4	15.6	17.1	0.6	0.7	14.0
BOSCH	18,449	Neutral	20,147	33.9	29.2	23.1	19.6	15.9	17.9	1.0	1.2	16.0
Endurance Tech	1,151	Buy	1,476	33.1	25.7	15.0	12.0	20.7	22.8	0.5	1.0	24.1
Motherson Sumi	165	Buy	204	31.4	22.0	10.2	7.3	16.8	21.0	0.8	1.2	18.1
CEAT	1,165	Buy	1,370	18.0	14.1	9.4	8.1	9.6	11.2	0.6	0.8	13.6

Comparative valuations

Source: MOFSL



Trade deficit at 17-month lowest in February 2019

- India's merchandise trade deficit fell to USD9.6b in Feb'19 from USD12.3b in the year ago month and an average of USD15.7b during the last six months. The number was substantially lower than both our and market expectation of USD11.4b and USD13.7b, respectively.
- India's exports rose by 2.5% YoY to USD26.7b in Feb'19 after rising by ~10% on average during Apr-Jan'19. While oil exports declined by 7.7% YoY to USD3.1b, non-oil exports rose by 4% YoY to USD23.6b in the month as against an average growth of ~7% during Apr-Jan'19. Among non-oil items, exports of engineering goods, India's top export segment, rose by 1.7% YoY to USD6.7b in Feb'19. While exports of drugs & pharmaceuticals rose 16.1% and electronic goods rose 46.1%, gems & jewellery exports fell 2.1% YoY in the month.
- India's imports, however, fell 5.4% in Feb'19 at USD36.3b and an average of ~13% during the last ten months. Oil imports fell by 8.1% YoY to USD9.4b, while gold imports fell 10.8% YoY to USD2.6b. Non-oil non gold & silver imports declined by 3.7% YoY in Feb'19 as against an average growth of ~6% seen during Apr-Jan'19. Among major non-oil non-gold items, imports of precious stones declined by 17.5%, transport equipment by ~20% and silver sharply by ~40%.
- The merchandise trade deficit stood at USD165.5b during Apr'18-Feb'19, up from USD148.6b in the year ago period. While exports rose by 8.9% YoY, imports grew 9.8% during the period.





Healthcare

Performance of top companies: February 2019)									
Company	MAT gr (%)	Feb-19 (%)							
IPM	9.6	10.0							
Sun Pharma	7.1	7.2							
ABBOTT*	11.3	8.9							
Cipla	8.9	10.7							
Zydus Cadila	7.3	10.7							
Mankind	10.6	12.6							
Alkem	10.9	10.2							
Lupin	15.5	16.6							
Torrent Pharma	13.1	19.8							
Pfizer	5.4	6.4							
Glenmark Pharma	15.0	10.6							
Sanofi	10.1	14.0							
Dr Reddy Labs	9.9	6.1							
GSK Pharma	5.0	7.4							
Alembic Pharma	11.2	11.6							
Ipca Labs	19.3	32.5							
Natco	5.0	4.4							
Ajanta Pharma	10.1	5.0							
Merck	6.3	6.1							
Biocon	17.0	9.8							

Slight pick-up in volumes; Price growth remains the key


- The Indian pharmaceutical market (IPM) witnessed a moderation in secondary sales in Feb'19. Sales increased 10% YoY as against 11.3% YoY in Jan'19. Growth was led by prices (up 4.9% YoY), volumes (up 2.7% YoY), and new launches (up 2.4% YoY).
- For the quarter ending Feb'19, IPM growth was at 10.4% YoY, supported by prices (up 4.9% YoY) and volumes (up 3% YoY). New product launches were up 2.4% YoY.
- The YoY growth on MAT basis was stable at 9.6% for 12M ending Feb'19.

Gradual improvement in volume growth for Non-DPCO drugs supports overall growth

- In value terms, secondary sales grew 10.4% YoY for non-DPCO products (86% of IPM) and 6.2% YoY for DPCO-listed products (10% of IPM) during the month.
- For non-DPCO products, the YoY growth for the month was spread across prices (up 5% YoY), volumes (up 2.7% YoY) and new products (up 2.7% YoY).

Ipca, Natco and Torrent remain growth leaders for Feb'19

- Growth momentum in secondary sales continued on superior execution in Ipca with 33% YoY growth (25-60% growth in top-10 products). Anti-infectives and blood-related therapy led 22.6% YoY growth in Natco. Torrent Pharma saw an upsurge of 21% YoY in sales, led by >20% growth in Cardiac, Gastrointestinal, Pain/Analgesics, Anti-Diabetic and Derma.
- GSK (up 5.6% YoY), Sun Pharma (up 7.8% YoY) and Pfizer (up 7.9% YoY) saw subdued growth for the quarter ending Feb'19 v/s IPM growth of 10.4% YoY.
- Particularly, for Feb'19, Ajanta exhibited lower YoY growth of 5% compared to MAT growth of 10%.
- Ipca reported highest price growth (+5.7%) and volume growth (+13.8%) on MAT basis, while Natco witnessed highest new product launches (+15.7%) on MAT basis.



Source: AIOCD, MOFSL

Anti-Diabetic, Cardiac and Anti-Neoplastics lead among therapies

- Within Chronic therapies, Anti-Diabetic reported the highest growth in the IPM (+18.6% YoY; 9.6% of IPM), followed by Cardiac (+16% YoY; 12.6% of IPM) for the quarter ending Feb'19. This can be partly attributed to the low base of past year. Anti-Neoplastics (2.2% of IPM) grew 11.6% YoY for the quarter.
- Respiratory (+3.3%; 7.5% of IPM) and Anti-infective (+5.4% YoY; 13.5% of IPM) underperformed the IPM. Vaccines continued seeing a decline in sales for the quarter ending Feb'19.

Both Indian and MNCs exhibited similar YoY growth

FDC-banned drugs (~0.3% of IPM) declined ~51% during the month, while, non-FDC (~48% of IPM) and single molecules (~51% of IPM) rose ~10.6% and ~10.3%, respectively. Secondary sales for Indian companies grew 10.2% YoY, while the MNCs were almost at par with 10% YoY growth in Feb'19.




Cement

Price hikes taken in Feb'19 moderate in Mar'19

Future hikes look difficult in the run-up to the elections

All-India prices increased 3%QoQ in 4QFY19

National Average Prices (INR/bag)



Only 1% QoQ price hike in the North led by rollback of declared price hikes Prices in North India increased by INR2/bag MoM in Feb'19, but were flat in Mar'19. The Delhi-NCR region witnessed hike of INR20/bag in Feb'19 in the non-trade segment. However, hikes announced in the trade segment were not sustainable. Demand in Rajasthan declined drastically after the state elections; while INR12/bag price hike was announced in Feb'19, only INR7/bag was sustainable. Prices in Punjab and Haryana were steady as the region faced problems on availability of sand and aggregates.

No price improvement in the East

Prices in the eastern region increased by INR3/bag to INR285/bag in Feb'19, with a price increase in the range of INR5/bag in Kolkata and Bihar. The region witnessed limited supply from southern players during this time. The supply of clinker was also affected due to shortage of wagons. But, the eastern region witnessed a decline in prices by INR3/bag in Mar'19 led by INR10/bag decline in prices in Kolkata. This resulted in flat QoQ prices in the East during 4QFY19.

Healthy show in the West led by Maharashtra

Prices in Mumbai increased by INR10/bag in the trade and non-trade segment in Feb'19. Nagpur, too witnessed an increase of INR20/bag in Feb'19 in the non-trade segment. Pune saw healthy INR30/bag hike in the month. The region also witnessed reduction in dispatches from the South. As a result, prices in the West increased by INR14/bag MoM in Feb'19. Prices increased by INR5/bag in Mar'19, which was led by INR10/bag increase in Mumbai and Pune, and flat prices in Nagpur and Ahmedabad. Overall, prices in the West improved by a healthy rate of 5% QoQ.

The South — a show stealer in Feb'19; but hikes fail to sustain in Mar'19

In Feb'19, companies announced price hikes to the extent of INR30-50/bag in the South. While Chennai saw a sustainable INR30/bag hike, the quantum was ~INR50/bag for Hyderabad, Bangalore and Kerala.

Cement production in the region was also curtailed with companies deciding not to sell OPC cement (an ordinary portland cement with lower margins). Also, blending OPC cement with fly-ash and selling it at a lower price by unorganized players is rampant in the South. But, it is now coming under control as organized players have decided against supplying OPC cement to smaller players. Overall prices improved by INR45/bag MoM in February in the southern region.

However, these hikes couldn't sustain as March approached because of selling pressure in the month due to the year-end and the lack of demand. As a result, prices corrected to the extent of INR20/bag in Hyderabad, Kerala and Bangalore, while they remained constant in Chennai. Increase in prices in the South is 5% QoQ.

Prices in Central India grew slow and steady

Prices in Central India increased by INR7/bag in Feb'19 led by INR10/bag hike in Lucknow and INR3/bag hike in Bhopal. The price increase in the region was INR2/bag MoM in Mar'19 led by INR3/bag hike in Bhopal and flat prices in Lucknow. Prices in the central region increased 2% QoQ in 4QFY19.

Valuation view

While all-India prices increased 3% QoQ in 4QFY19, we believe there should not be any further price hikes in any of the regions, at least till the general elections conclude. Some of these regions are facing labor shortage issues, while liquidity crunch due to non-payment is still prevalent in various regions.

We prefer companies with higher exposure to the northern region, as the North is pegged to witness maximum improvement in capacity utilization over the next two years. Our top pick to play the North theme is **SRCM**. We also like **ACC**, which is on a growth capex mode and should witness improvement in profitability.

- ACC: The company is planning to add 6mt capacity at a total capex of INR30b (~USD71/t), which will come on stream over the next three years. This will be funded by internal accruals, helping the company protect its market share in the central and eastern regions. ACC's profitability gap with peers has narrowed significantly over the last few quarters, led by higher proportion of (a) premium sales, and (b) sales from its new cost-efficient units of Jamul and Sindri. The company has also done well to manage costs, driven by higher proportion of linkage coal, lower lead distance and route optimization. Besides this, ACC is trying to rationalize fixed costs. The stock trades attractively at 7x CY20 EV/EBITDA. With growth concerns being addressed, the valuation discount of over 40% to large caps on EV/ton and EV/EBITDA should narrow substantially. We value ACC at 9x CY20E EV/EBITDA to arrive at a target price of INR1,853.
- SRCM: SRCM's relatively low cost of production compared to peers has resulted in healthy margins and return ratios. As a result, we believe it warrants premium valuations. We expect SRCM to deliver a better-than-industry performance due to (a) capacity ramp-up over FY19-21 (company plans to increase domestic capacity by ~22% at an estimated cost of USD25/t), and (b) favorable market mix, with higher exposure to the northern markets (~70%), where prices are expected to be healthy. We value SRCM at 15x FY21 EV/EBITDA and arrive at a target price of INR21,017.

		ROE (%)				PE (x)			/EBITDA	(x)	EV/Ton (USD)		
	СМР	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E	FY19E	FY20E	FY21E
ACC	1,540	10.8	13.3	14.4	26.9	19.6	16.2	12.0	8.9	7.0	106	96	88
ACEM	225	6.1	6.2	6.8	24.2	22.3	19.7	13.9	12.1	10.6	123	120	123
UTCEM	3,965	7.9	9.5	10.6	51.3	37.7	28.6	19.3	15.9	13.2	180	165	154
SRCM	17,688	14.3	15.6	17.1	46.4	37.9	30.0	20.1	15.7	12.5	207	177	161
BCORP	536	4.6	8.3	10.9	20.9	11.0	7.7	8.3	6.6	5.4	65	66	64
ICEM	87	1.1	2.8	4.1	53.0	21.2	14.2	10.0	8.1	7.2	55	54	55
JKCE	831	12.8	13.0	12.8	24.2	21.5	19.7	8.8	9.9	8.4	82	77	73
JKLC	351	4.9	8.4	12.6	56.6	31.1	18.9	12.4	9.6	7.3	60	56	51
MCEM	717	11.0	12.3	14.1	36.2	29.3	22.8	17.7	15.4	11.9	140	126	120
ORCMNT	87	-0.8	6.0	10.7	-220.4	29.1	15.1	13.1	9.4	6.7	51	46	35
PRISM	97	12.6	14.2	14.2	36.0	28.6	25.4	11.4	10.6	10.1	74	70	69
SNGI	60	2.5	3.3	3.3	32.3	24.1	23.5	13.7	13.3	8.2	46	45	45

Cement: Valuation summary






1. V-MART RETAIL: WILL OPEN MORE STORES IN THE NEXT 18 DAYS; Lalit Agarwal, CMD

- Saw some softness in the market during December and January. Have started seeing early pick up due to Holi.
- Q4 same-store-sales growth should be somewhere around mid-single digit growth.
- Next year should have a good base to start from. See a lot of activities even from the government side resulting into economic upcoming of people, a lot of work which has happened in the past 7-8 months and also things that will come up in coming days should add a lot of economic upswing in public consumption space.
- Company continues its store opening plan. Have already opened 37 stores in this fiscal year and yet to announce some of the stores. Company has opened 37 and have a plan to open more in the remaining 18 days also. Will target more in next year also.

Read More

- 2. CONCOR: MAINTAIN FY19 VOLUME GROWTH OF 10-12%; V Kalyana Rama, CMD
- There is a little slowdown in export-import but for March, the forecast is that from second fortnight of March things may improve.
- Will be ending year as company has forecasted. Company gave a forecast of 10-12 percent growth.
- As far as domestic volumes are concerned, domestic business is good, there is no such worry in the domestic volumes.
- With the dedicated freight corridor, will see real benefit from FY21.



MOTILAL OSWAL MOIND





1. BANKING SECTOR TO BECOME LESS LABOUR-INTENSIVE, AUTOMATION THE WAY FORWARD

The creation of jobs has always been the focal point of debates in the country. The banking sector has been a large employer with a 1.3 million workforce in 2017-18, up from 1.1 million in 2012-13. The question is whether or not this number has been increasing at a significant pace and, if there has been any change in the composition of the same. A five-year period has been considered from 2012-13 to 2017-18. The CAGR was 4%, which is just about the industry standard given that services tend to involve more jobs. The banking business, on the other hand, has been increasing at a far higher rate than that in the stock of workforce. The graphic shows that the dominant segment has been private banks that have expanded at a sharper rate than the PSBs which had an increase of just 1.1%. The private banks' growth number is slightly on the higher side given the mergers that have taken place with other institutions. But their share has increased from around 25% to 32% during this period. The interesting part here is that the two non-officer categories have shown a distinct declining trend with there being a shrinkage in the clerks and sub-staff categories. The ratio of clerks and sub-staff to officers was still above 1 for PSBs at 1.09 while it was low at 0.09 and 0.06 respectively for private and foreign banks. But PSBs have lowered this ratio from 1.39 in 2012-13 and private banks from 0.39 the same year. This means that banks across all categories are following a similar pattern in terms of staffing.

Read More

2. LOK SABHA POLLS: COMMON MINIMUM PROBLEMS OF THE OPPOSITION

India will vote in seven phases, starting April 11 to elect the 17th Lok Sabha, which will pave the way for the formation of the next government. Votes will be counted on May 23. According to a recent CVoter opinion poll, the ruling Bharatiya Janata Party (BJP)-led National Democratic Alliance (NDA) is likely to win 264 of the 543 seats in the lower house of the Parliament. The Congress-led United Progressive Alliance (UPA) is likely to bag 141 seats. This should not be surprising as the NDA, led by Prime Minister Narendra Modi, is widely seen to be in a stronger position. This is supported by the fact that the Congress and other opposition parties, so far, have not been able to pose a formidable challenge. Though after the December 2018 assembly polls it looked like the momentum was shifting away from the BJP and towards the Opposition, public sentiment appears to have changed significantly after the Indian Air Force attacked terror base camps operated by the Jaish-e-Mohammed (JeM), deep inside Pakistan.



3. THE CASE FOR A BOLD ECONOMICS

At the end of 1933, John Maynard Keynes sent a remarkable public letter to US President Franklin Delano Roosevelt. FDR had taken office earlier that year, in the midst of an economic slump that had pushed a quarter of the labor force into unemployment. He had launched his ambitious New Deal policies, including public works programs, farm subsidies, financial regulation, and labor reforms. He had also taken the US off the gold standard to give domestic monetary policy freer rein. Keynes approved of the general direction of these policies, but also had some sharp criticism. He worried that FDR complicated the economic recovery effort by broadening his policy agenda unnecessarily. FDR was doing too little to increase aggregate demand and too much to change the rules of the economy. Keynes took particular aim at the National Industrial Recovery Act, which, among other things, greatly expanded labor rights and fostered independent unions. He fretted that the NIRA would sap business confidence and weigh on the federal bureaucracy, without making a direct contribution to recovery. He wondered whether some of the advice FDR was getting "is not crack-brained and queer." Keynes did not think much of FDR's economics, but at least he was a sympathetic critic.





Click excel icon for detailed valuation guide

		СМР	ТР	% Upside	E	EPS (INF	R)	EPS	Gr. Yo	Y (%)	P/E	(x)	P/B	(x)	ROE	E (%)
Company	Reco	(INR)	(INR)	Downside	FY18	FY19E	FY20E	FY18	FY19E	FY20E			FY19E	FY20E	FY19E	FY20E
Automobiles																
Amara Raja	Buy	746	855	15	27.6	28.6	35.9	-1.5	3.7	25.5	26.1	20.8	3.8	3.3	15.6	17.1
Ashok Ley.	Buy	94	110	17	6.0	7.0	7.3	37.1	18.3	4.0	13.3	12.8	3.3	2.9	26.7	24.1
Bajaj Auto	Buy	3022	3045	1	151.3	159.2	177.1	7.3	5.2	11.3	19.0	17.1	4.1	3.7	22.8	22.8
Bharat Forge	Buy	534	568	6	18.4	23.8	27.3	40.7	28.9	15.1	22.5	19.5	4.5	3.9	21.9	21.5
Bosch	Neutral	18449	20147	9	469.8	543.9	632.3	-0.7	15.8	16.2	33.9	29.2	5.1	5.5	15.9	17.9
CEAT	Buy	1165	1370	18	64.0	64.7	82.5	-30.3	1.1	27.5	18.0	14.1	1.7	1.5	9.6	11.2
Eicher Mot.	Buy	22632	23960	6	799.6	855	1,000	27.0	7.0	16.9	26.5	22.6	7.0	5.7	29.5	27.7
Endurance Tech.	Buy	1151	1476	28	29.1	34.7	44.8	23.8	19.5	28.9	33.1	25.7	6.4	5.4	20.7	22.8
Escorts	Neutral	799	754	-6	39.5	54.6	60.5	88.0	38.3	10.7	14.6	13.2	2.7	2.3	20.0	18.8
Exide Ind	Buy	229	280	22	8.2	8.9	10.9	0.4	9.1	21.5	25.6	21.1	3.3	3.0	12.7	14.1
Hero Moto	Neutral	2739	2928	7	185.1	171.9	181.0	9.5	-7.2	5.3	15.9	15.1	4.3	4.1	28.1	27.7
M&M	Buy	693	841	21	41.0	41.5	47.5	49.8	1.2	14.2	16.7	14.6	2.4	2.2	14.5	14.1
Maruti Suzuki	Buy	7092	8131	15	266.7	244.8	291.8	7.3	-8.2	19.2	29.0	24.3	4.7	4.3	16.3	17.4
Motherson Sumi	Buy	165	204	23	5.4	5.3	7.5	6.0	-2.4	43.0	31.4	22.0	5.0	4.3	16.8	21.0
Tata Motors	Neutral	180	166	-8	22.9	-4.4	17.2	15.7	PL	LP	NM	10.5	0.9	0.9	-1.8	8.5
TVS Motor	Neutral	493	576	17	13.9	15.2	22.0	18.7	9.0	44.7	32.4	22.4	6.9	5.7	23.1	27.8
Aggregate								15.8	-21.8	40.7	26.2	18.6	3.3	3.0	12.7	16.2
Banks - Private	Deser	600	720	10	10.2	12.0	47.4	70 5	20	22.2	47.4	25.0			42.0	12.0
AU Small Finance	,	609	720	18	10.2	12.9	17.1	-79.5	26	32.3	47.1	35.6	5.7	4.4	13.8	13.9
Axis Bank	Buy	736	850	16	1.1	18.5	39.6	-92.8	1,568	113.5	39.7	18.6	2.8	2.4	7.2	13.9
DCB Bank	Neutral	201	175	-13	8.0	10.2 6.8	13.2	13.8	27.6	30.1 40.6	19.8	15.2	2.1	1.9	11.6	13.4
Equitas Hold. Federal Bank	Buy	135 91	150 115	12 26	0.9 4.8	6.1	9.5 8.9	-82.3 -1.3	631.5 29.3	40.6	19.9 14.9	14.1 10.3	1.8 1.4	1.7 1.2	9.7 9.5	12.4
HDFC Bank	Buy	2252	2500	11	4.0 67.8	79.8	95.9	-1.5	17.6	20.2	28.2	23.5	4.1	3.6	9.5	12.5
ICICI Bank	Buy Buy	396	450	11	11.1	79.8	20.2	-34.3	-30.8	163.7	51.7	19.6	2.4	2.2	4.7	11.8
IndusInd	Buy	1701	1900	14	60.2	68.8	100.2	25.2	14.3	45.6	24.7	17.0	3.9	3.1	16.5	20.2
Kotak Mah. Bk	Neutral	1325	1350	2	32.5	37.9	46.1	21.3	16.4	21.7	35.0	28.7	4.4	3.8	12.1	13.3
RBL Bank	Buy	647	650	0	15.1	20.6	28.0	27.3	36.4	35.6	31.4	23.1	3.7	3.3	12.3	14.9
South Indian	Buy	16	20	29	1.9	1.7	2.7	-25.5	-10.5	61.1	9.4	5.8	0.5	0.5	5.6	8.6
Yes Bank	Buy	245	270	10	18.4	18.5	22.6	26.3	0.4	22.4	13.2	10.8	1.9	1.7	15.5	16.7
Aggregate	- 1	-		-				-1.3	22.2	49.5	30.4	20.3	3.3	2.9	10.8	14.3
Banks - PSU																
вов	Buy	118	140	19	-9.8	8.9	15.7	PL	LP	77.5	13.3	7.5	0.7	0.7	5.3	8.8
BOI	, Neutral	93	90	-3	-43.2	-24.4	3.7	Loss	Loss	LP	NM	25.0	0.7	0.7	-15.0	2.7
Canara	Neutral	265	278	5	-63.5	17.0	42.3	PL	LP	148.5	15.6	6.3	0.6	0.5	3.5	8.2
Indian Bk	Buy	266	300	13	26.2	15.3	30.4	-10.4	-41.7	98.8	17.4	8.8	0.7	0.7	4.6	8.6
PNB	Neutral	86	80	-7	-50.3	-14.4	8.0	PL	Loss	LP	NM	10.7	0.8	0.7	-11.0	6.6
SBI	Buy	298	340	14	-5.3	6.6	30.0	PL	LP	354.4	45.1	9.9	1.2	1.1	1.8	11.5
Union Bk	Neutral	83	80	-4	-56.5	4.5	12.8	PL	LP	185.8	18.5	6.5	0.4	0.3	2.1	5.5
Aggregate								PL	LP	9,703.7	906.4	9.2	0.9	0.8	0.1	8.8
NBFCs																
Aditya Birla Cap	Buy	99	145	46	3.8	4.1	5.3	NA	10.4	27.2	23.9	18.8	2.2	1.9	10.2	11.3
Bajaj Fin.	Neutral	2860	2400	-16	43.4	68.3	89.1	35.9	57.4	30.5	41.9	32.1	8.7	7.0	22.8	24.2
Cholaman.Inv.&F n	Buy	1388	1525	10	62.3	78.1	88.4	35.5	25.4	13.2	17.8	15.7	3.5	2.9	21.8	20.4
HDFC	Buy	1977	2300	16	42.3	44.8	51.9	6.2	5.9	16.0	44.2	38.1	4.6	4.2	15.6	15.3
HDFC Life Insur.	Buy	370	475	28	5.5	6.4	7.6	23.7	16.6	18.3	57.4	48.5	4.1	3.5	18.6	19.1
ICICI Pru Life	Buy	340	430	26	11.3	8.0	8.9	-3.8	-29.0	11.0	42.5	38.3	2.2	2.0	15.7	14.9
Indiabulls Hsg	Buy	700	900	29	90.2	95.9	110.2	31.5	6.3	14.9	7.3	6.4	1.8	1.6	25.7	26.2
L&T Fin Holdings	•	147	185	26	6.8	11.5	13.3	29.5	69.5	15.6	12.8	11.0	2.2	1.9	18.8	18.5
LIC Hsg Fin	, Buy	510	600	18	39.4	47.7	56.1	3.0	21.1	17.7	10.7	9.1	1.6	1.4	15.6	16.1
MAS Financial	Buy	567	650	15	19.2	28.4	32.6	27.5	47.9	15.1	20.0	17.4	3.7	3.2	19.8	19.6
M&M Fin.	, Buy	435	518	19	17.4	21.7	27.0	146.3	24.1	24.5	20.1	16.1	2.5	2.3	13.2	14.9
Muthoot Fin	, Neutral	598	500	-16	43.0	48.9	57.1	45.6	13.8	16.8	12.2	10.5	2.6	2.2	23.2	23.0
				-	-			-					-			-



Click excel icon for detailed valuation guide

1

		СМР	ТР	% Upside	F	PS (INF	2)	FPS	Gr. Yo	Y (%)	P/E	(x)	P/B	(x)	ROF	E (%)
Company	Reco	(INR)	(INR)	Downside			FY20E		FY19E	FY20E					FY19E	<u> </u>
PNB Housing	Buy	876	1100	26	49.6	66.0	78.0	56.9	33.0	18.2	13.3	11.2	2.0	1.8	16.1	16.8
Repco Home	Buy	454	480	6	32.9	38.8	44.4	13.1	17.7	14.4	11.7	10.2	1.9	1.6	17.2	16.8
Shriram City Union	Buy	1763	2000	13	100.8	144.2	158.0	19.5	43.1	9.6	12.2	11.2	1.9	1.6	16.3	15.5
Shriram Trans.	Buy	1267	1400	10	69.1	108.7	133.3	24.7	57.3	22.6	11.7	9.5	1.8	1.6	16.8	17.8
Aggregate								25.1	21.3	18.8	25.5	21.5	3.9	3.4	15.2	15.9
Capital Goods																
ABB	Sell	1304	1020	-22	10.6	12.0	17.4	-41.9	12.7	44.8	108.7	75.1	6.9	6.4	6.3	8.6
Bharat Elec.	Buy	95	110	16	5.7	7.1	7.4	-8.8	24.0	4.1	13.3	12.8	2.6	2.3	19.7	18.3
BHEL	Sell	68	47	-31	2.2	3.2	3.8	62.7	45.5	18.6	21.2	17.9	0.8	0.7	3.5	4.2
Blue Star	Neutral	665	620	-7	14.5	16.8	23.6	12.7	15.6	40.5	39.6	28.2	7.0	6.3	19.3	22.3
CG Cons. Elec.	Buy	228	270	18	5.2	6.0	7.7	14.3	16.1	28.6	38.1	29.6	14.6	11.6	42.4	43.7
Cummins	Buy	741	950	28	23.5	26.9	30.7	-11.2	14.4	13.9	27.5	24.1	4.8	4.4	18.0	19.0
Engineers India	Buy	114	145	27	6.3	6.4	7.4	14.8	1.6	17.1	17.9	15.3	3.1	2.8	16.9	18.0
GE T&D	Neutral	293	280	-4	7.5	10.1	11.1	30.8	35.2	9.4	28.9	26.4	5.6	4.9	20.4	19.7
Havells	Buy	746	820	10	11.2	13.2	16.2	17.4	17.3	22.8	56.7	46.2	11.0	9.7	19.4	20.9
K E C Intl	Neutral	299	260	-13	17.9	19.7	24.7	51.1	10.2	25.2	15.1	12.1	3.2	2.6	20.9	21.5
L&T	Buy	1397	1610	15	51.7	59.1	73.0	22.4	14.3	23.5	23.7	19.1	3.2	2.5	14.2	14.6
Siemens	Neutral	1034	1125	9	19.8	25.1	30.9	10.9	27.1	23.1	41.2	33.5	4.4	4.1	11.2	12.7
Solar Ind	Neutral	1033	1125	9	24.4	28.7	37.5	18.2	17.9	30.6	35.9	27.5	7.2	6.0	21.9	23.8
Thermax	Buy	1016	1240	22	20.5	26.3	36.3	-1.2	28.0	38.4	38.7	27.9	3.9	3.5	10.5	13.2
Va Tech Wab.	Neutral	323	300	-7	24.1	26.3	33.6	27.6	9.3	27.6	12.3	9.6	1.4	1.3	10.9	14.1
Voltas	Neutral	600	590	-2	17.3	15.4	17.5	11.9	-11.1	14.1	39.0	34.2	4.6	4.2	12.7	12.9
Aggregate								14.5	16.4	21.1	27.4	22.6	3.3	2.8	12.0	12.4
Cement	-				_											
Ambuja Cem.	Neutral	225	194	-14	6.1	6.3	6.8	31.6	2.3	8.5	35.9	33.1	2.1	2.1	6.1	6.3
ACC	Buy	1533	1853	21	46.9	57.3	78.4	27.7	22.1	36.9	26.8	19.6	2.7	2.5	10.8	13.3
Birla Corp.	Buy	536	590	10	18.9	25.6	48.6	-35.6	35.5	89.8	20.9	11.0	0.9	0.9	4.6	8.3
Grasim Inds.	Neutral	830	836	1	47.3	62.6	80.8	-30.2	32.4	28.9	13.2	10.3	1.2	1.1	6.0	6.1
India Cem	Neutral	98	81	-17	3.3	1.9	4.8	-42.0	-41.3	150.3	50.9	20.4	0.6	0.6	1.1	2.8
J K Cements	Buy	830	825	-1	41.0	34.3	38.7	56.2	-16.3	12.8	24.2	21.4	2.9	2.7	12.8	13.0
JK Lakshmi Ce	Buy	352	386	10	7.4	6.2	11.3	6.4	-16.4	81.8	56.9	31.3	2.7	2.5	4.9	8.4
Ramco Cem	Buy	704 86	680	-3	24.0	19.8	24.5 3.0	-11.9	-17.4	23.8	35.6	28.8	3.7	3.4 1.7	11.0	12.3
Orient Cem Prism Johnson	Buy Buy	91	82 100	-5 10	2.2 1.4	-0.4 2.7	3.0	LP 302.1	PL 92.4	LP 25.7	NM 33.9	28.8 26.9	1.8 4.1	3.6	-0.8 12.6	6.0 14.2
		61	67	10	3.7	1.6	2.2	29.5	-56.0	33.9	37.2	20.9	0.9	0.9	2.5	3.3
Sanghi Inds. Shree Cem	Buy Buy	17576			385.8	380.9	466.1	0.4	-30.0	22.4	46.1	37.7	6.3	5.5	14.3	5.5 15.6
Ultratech	Buy	3917	4368	12	85.7	77.3	105.2	-10.9	-9.8	36.1	50.7	37.2	3.9	3.1	7.9	9.5
Aggregate	Duy	5517	4300	12	05.7	11.5	105.2	10.5	8.0	31.4	29.4	22.4	2.4	2.2	8.3	10.0
Consumer								1.7	0.0	51.4	23.4	22.4	2.7	2.2	0.5	10.0
Asian Paints	Neutral	1432	1500	5	21.1	23.9	28.4	1.9	13.3	18.5	59.8	50.5	15.1	14.3	26.2	29.1
Britannia	Buy	3070	3630	18	41.8	48.4	59.1	13.5	15.6	22.2	63.5	51.9	19.2	18.0	32.1	35.8
Colgate	Buy	1273	1540	21	25.2	27.9	32.1	18.6	10.8	15.1	45.6	39.7	21.5	21.4	48.4	54.1
Dabur	Neutral	425	455	7	7.8	8.4	9.6	7.2	8.5	13.7	50.4	44.4	11.4	10.3	24.2	24.4
Emami	Buy	392	520	33	12.1	12.6	14.3	-8.5	4.2	12.9	31.0	27.5	8.2	7.9	27.4	29.2
Future Consumer	•	45	56	25	-0.2	-0.1	0.8	Loss	Loss	LP	NM	59.7	7.6	6.7	-1.9	11.9
Godrej Cons.	Neutral	705	805	14	14.1	14.9	17.7	11.4	5.6	18.9	47.4	39.9	10.5	9.7	23.2	25.3
GSK Cons.	Neutral	7070	7785	10	166.5	206.1		6.6	23.8	8.6	34.3	31.6	8.3	7.4	24.5	24.7
HUL	Buy	1699	2125	25	24.5	28.8	34.3	24.7	17.5	19.1	59.0	49.6	49.8	50.5	86.1	101.2
ITC	Neutral	291	300	3	8.9	9.9	11.2	5.5	11.6	13.1	29.4	26.0	7.1	6.6	23.8	26.2
Jyothy Lab	Neutral	185	190	3	4.9	5.3	6.5	-12.4	8.7	22.2	34.6	28.3	5.5	5.2	16.5	18.9
Marico	Buy	339	470	38	6.4	7.5	8.9	2.0	16.9	18.7	45.3	38.2	15.0	13.7	35.4	37.5
Nestle	Neutral	10329			140.0	178.6		13.2	27.5	10.5	57.8	52.4	27.1	26.7	48.5	51.4
Page Inds	Neutral	23615			311.1		472.0	30.3	21.6	24.7	62.4	50.0	32.1	26.9	51.5	53.8
Parag Milk Foods		254	260	2	10.4	13.9	16.1	383.7	33.5	16.3	18.3	15.8	2.6	2.3	15.2	15.5
	- 1	•		_												





Click excel icon for detailed valuation guide

1

CompanyReco(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN)(INN) <t< th=""><th></th><th></th><th>СМР</th><th>ТР</th><th>% Upside</th><th>E</th><th>EPS (INF</th><th>र)</th><th>EPS</th><th>Gr. Yo</th><th>Y (%)</th><th>P/E</th><th>(x)</th><th>P/B</th><th>; (x)</th><th>ROE</th><th>E (%)</th></t<>			СМР	ТР	% Upside	E	EPS (INF	र)	EPS	Gr. Yo	Y (%)	P/E	(x)	P/B	; (x)	ROE	E (%)
PAG Hygener Neutral 10243 8800 -5 11.39 13.40 23.00 26.80 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00 21.00	Company	Reco			•		•										<u> </u>
United pointsNeutral13801880170114015016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.0 <td>Pidilite Ind.</td> <td>Buy</td> <td>1167</td> <td>1280</td> <td>10</td> <td>18.9</td> <td>18.2</td> <td>22.4</td> <td>13.2</td> <td>-4.0</td> <td>23.2</td> <td>64.2</td> <td>52.1</td> <td>14.9</td> <td>13.6</td> <td>24.4</td> <td>27.3</td>	Pidilite Ind.	Buy	1167	1280	10	18.9	18.2	22.4	13.2	-4.0	23.2	64.2	52.1	14.9	13.6	24.4	27.3
United pointsNeutral13801880170114015016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.016.0 <td>P&G Hygiene</td> <td>Neutral</td> <td>10294</td> <td>9800</td> <td>-5</td> <td>113.9</td> <td>134.4</td> <td>167.0</td> <td>-14.5</td> <td>18.0</td> <td>24.3</td> <td>76.6</td> <td>61.6</td> <td>35.5</td> <td>30.1</td> <td>50.0</td> <td>53.0</td>	P&G Hygiene	Neutral	10294	9800	-5	113.9	134.4	167.0	-14.5	18.0	24.3	76.6	61.6	35.5	30.1	50.0	53.0
Aggregate 10.7 14.7 16.9 46.7 40.0 13.7 12.7 29.3 31.7 Heathbare Neutral 547 615 12 21.9 29.3 29.6 2.5 33.8 1.2 18.7 18.5 3.9 3.4 22.4 19.3 Alkern Lab Buy 1015 1390 37 53.0 43.7 12.7 29.8 18.7 23.2 19.6 38.3 22.4 19.3 35.5 3.1 18.8 32.1 16.6 18.4 32.2 17.5 17.7 20.6 2.0 38.1 18.0 21.0 23.1 18.8 17.1 21.0 23.1 18.8 52.4 19.3 35.5 3.1 18.8 17.1 22.6 22.0 28.2 27.7 59.4 30.5 30.6 30.6 31.7 14.7 14.9 29.2 22.7 28.2 27.8 28.2 28.2 28.2 28.2 28.2 28.2 28.2		Neutral	1384	1480	7	14.9	23.0	26.8	71.7	54.0	16.6	60.3	51.7	11.4	9.5	20.6	20.1
Healthcare Alembic Phar Neutral 24 615 12 219 29.3 29.6 2.5 33.8 1.2 1.8 3.5 3.9 3.4 21.4 19.3 Alembic Phar Buy 1750 2855 58.9 72.4 91.8 -11 22.9 26.8 24.2 19.1 3.8 3.3 20.6 12.8 3.2 12.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.6 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 13.0 <	United Spirits	Buy	583	700	20	6.7	10.3	14.2	26.1	53.3	37.4	56.3	41.0	13.6	10.8	24.2	26.3
Alembic Plar Neutral 547 615 12 213 236 24 93 246 25 38 12 18 18 18. 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.	Aggregate								10.7	14.7	16.9	46.7	40.0	13.7	12.7	29.3	31.7
Alken Buy 1750 2365 350 72.4 91.8 21.1 22.9 28.8 24.7 18.8 3.1 18.8 3.2 17.5 Alpanta Pharm Buy 171 940 22 42.7 42.8 51.8 7.5 17.5 18.7 23.2 18.4 3.2 2.6 3.3 3.5 3.1 3.2 2.6 3.3 9.0 3.3 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3	Healthcare																
Ajanta Pharma Buy 1016 1390 37 53.0 43.7 51.0 7.5 7.7 18.7 23.2 18.6 3.8 3.2 17.5 17.5 Aurobino Buy 771 940 22 42.7 42.8 59.1 8.7 0.2 84.8 1.8 1.4 84.5 1.4 84.5 1.4 84.5 1.6 34.2 28.6 6.4 1.6 1.6 34.2 9.6 1.6 1.6 34.2 9.6 1.6 34.2 9.6 1.6 34.2 1.6 1.6 34.2 1.6 1.6 34.2 1.6 1.6 34.2 1.6 1.6 34.2 1.6 1.6 34.2 1.6 1.2 1.6 3.6 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.6 1.2 1.2	Alembic Phar	Neutral	547	615	12	21.9	29.3	29.6	2.5	33.8	1.2	18.7	18.5	3.9	3.4	22.4	19.3
Aurobindo Buy 771 940 22 42.8 91.1 27.0 28.1 18.0 1.1.1 3.2 2.6 10.6 2.2 Biocon Neural 623 680 10 6.2 11.9 21.8 27.7 20.6 3.3 19.3 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.6 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 3.1 3.5 3.1 3.5 3.1 3.1 3.5 3.1 3.1 3.5 <td>Alkem Lab</td> <td>Buy</td> <td>1750</td> <td>2365</td> <td>35</td> <td>58.9</td> <td>72.4</td> <td>91.8</td> <td>-21.1</td> <td>22.9</td> <td>26.8</td> <td>24.2</td> <td>19.1</td> <td>3.8</td> <td>3.3</td> <td>16.6</td> <td>18.4</td>	Alkem Lab	Buy	1750	2365	35	58.9	72.4	91.8	-21.1	22.9	26.8	24.2	19.1	3.8	3.3	16.6	18.4
BioconNeutral623685106.21.102.129.749.748.355246.46.45.61.3017.0CadilaBuy342520-2.31.001.721.7.1.63.21.911.913.53.11.811.71Divis LoNeutral537520-2.02.031.805.61.121.103.23.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.03.0 </td <td>Ajanta Pharma</td> <td>Buy</td> <td>1016</td> <td>1390</td> <td>37</td> <td>53.0</td> <td>43.7</td> <td>51.9</td> <td>-7.5</td> <td>-17.5</td> <td>18.7</td> <td>23.2</td> <td>19.6</td> <td>3.8</td> <td>3.2</td> <td>17.5</td> <td>17.9</td>	Ajanta Pharma	Buy	1016	1390	37	53.0	43.7	51.9	-7.5	-17.5	18.7	23.2	19.6	3.8	3.2	17.5	17.9
Cadilia Buy 342 420 23 17.5 17.6 17.6 20.6 3.3 19.9 13.3 3.5 3.1 18.8 17.1 Cipla Neutral 17.0 170 170 18.0 17.1 18.2 17.1 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2 <th18.2< th=""> <th18.2< th=""> <th18.2< td="" th<=""><td>Aurobindo</td><td>Buy</td><td>771</td><td>940</td><td>22</td><td>42.7</td><td>42.8</td><td>59.1</td><td>8.7</td><td>0.2</td><td>38.1</td><td>18.0</td><td>13.1</td><td>3.2</td><td>2.6</td><td>19.6</td><td>22.2</td></th18.2<></th18.2<></th18.2<>	Aurobindo	Buy	771	940	22	42.7	42.8	59.1	8.7	0.2	38.1	18.0	13.1	3.2	2.6	19.6	22.2
CiplaNeutral532520-220.318.024.131.2-11.694.229.620.02.82.59.411.3Divis labNeutral26602540-564.710.912.9-10.969.417.369.569.417.369.569.417.369.569.417.369.569.417.369.569.417.369.569.417.469.569.417.469.569.417.469.569.417.469.569.417.469.569.417.469.569.417.469.569.417.469.569.417.417.517.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.417.41	Biocon	Neutral	623	685	10	6.2	11.9	21.8	-39.2	91.4	83.5	52.4	28.6	6.4	5.6	13.0	20.9
Divis Lab Neutral 1708 1570 -8 33.0 6.0 61.3 -7.3 69.5 9.4 9.0 5.0 5.0 5.1 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0	Cadila	Buy	342	420	23	17.5	17.2	17.7	20.6	-2.0	3.3	19.9	19.3	3.5	3.1	18.8	17.1
Dr Reddy's Neutral 2560 2540 -5 647 1096 129 -10 69.4 17.9 24.3 20.6 3.2 2.8 1.3 1.4 Genanles Neutral 140 140 25.6 10.4 22.6 10.1 22.6 10.1 5.1 1.0 1.2 1.6 1.6 1.6 1.8 1.6.3 1.7 1.8 1.6.3 1.7 1.8 1.6.3 1.7 1.8 1.6.3 1.7 1.8 1.6.3 1.7 1.8 1.6.1 1.2 21.5 1.8 1.6.1 1.2 1.5.0 1.7 1.8 1.6 1.1 1.8 1.6 1.1 1.8 1.8 1.6 1.1 1.8 1.8 1.6 1.1 1.8 1.8 1.6 1.1 1.8 1.8 1.6 1.1 1.8 1.8 1.4 1.8 1.4 1.8 1.4 1.8 1.8 1.8 1.1 1.8 1.8 1.8 1.	Cipla	Neutral	532	520	-2	20.3	18.0	24.1	31.2	-11.6	34.2	29.6	22.0	2.8	2.5	9.4	11.3
Glenmark Neutral 640 560 -12 28.9 28.7 27.5 6.0 2.2 21.6 1.0 2.0 1.6 1.0 2.0 1.6 2.1 Granules Nueutal 120 130 21 17 2.0 18.1 2.1 12.0 1.0 2.0 1.8 1.0 2.0 1.8 1.0 2.0 1.8 1.0 2.0 1.8 1.0 2.0 1.8 1.0 2.0 1.8 1.0 2.0 1.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <th1.0< th=""> 1.0 <th1.0< th=""> <th1< td=""><td>Divis Lab</td><td>Neutral</td><td>1708</td><td>1570</td><td>-8</td><td>33.0</td><td>56.0</td><td>61.3</td><td>-17.3</td><td>69.5</td><td>9.4</td><td>30.5</td><td>27.9</td><td>6.4</td><td>5.4</td><td>22.9</td><td>21.1</td></th1<></th1.0<></th1.0<>	Divis Lab	Neutral	1708	1570	-8	33.0	56.0	61.3	-17.3	69.5	9.4	30.5	27.9	6.4	5.4	22.9	21.1
Granules Buy 114 140 23 5.6 8.9 10.4 -23.2 60.1 16.5 12.8 11.0 2.0 1.8 16.3 17.0 GSK Pharma Neutal 12.99 1330 2 19.7 24.0 29.1 14.4 21.1 14.4 14.4 14.6 14.4 44.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.4 14.6 14.7 15.5 11.7 18.8 15.7 17.3 18.7 17.0 12.3 13.0 14.6 14.7 18.0 16.0 15.0 17.3 18.7 14.8 14.8 14.0 14.3 14.0 14.3 14.0 14.3 14.0 14.3 14.0 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 14.3 <th14.3< th=""> 14.3 14.3</th14.3<>	Dr Reddy's	Neutral	2660	2540	-5	64.7	109.6	129.2	-10.9	69.4	17.9	24.3	20.6	3.2	2.8	13.7	14.4
GSK PharmaNeutral12991330219,724,029,114,421,121,454,144,610,49,719,221,7IPCA LabsBuy886970919,035,342,518,186,120,325,210,03,61,611,0IpCA LabsBuy77510002732,025,938,343,518,947,832,522,02,72,58,511,9LupinBuy7721700022141,715,519,39,847,832,522,02,72,58,511,3SanofindiaBuy7271700022141,715,517,39,847,634,042,215,72,42,110,513,3Sindar MedicareBuy4385903112,812,22,44,51,114,81,61,31,39,843,547,01,31,41,61,51,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,41,41,41,41,81,51,41,41,41,41,41,41,41,41,41,41,41,41,41,41,4 <td>Glenmark</td> <td>Neutral</td> <td>640</td> <td>560</td> <td>-12</td> <td>28.5</td> <td>28.2</td> <td>34.7</td> <td>-27.5</td> <td>-0.9</td> <td>22.8</td> <td>22.7</td> <td>18.5</td> <td>3.0</td> <td>2.6</td> <td>13.2</td> <td>14.1</td>	Glenmark	Neutral	640	560	-12	28.5	28.2	34.7	-27.5	-0.9	22.8	22.7	18.5	3.0	2.6	13.2	14.1
PCA Labs Buy 886 970 9 19.0 35.3 42.5 18.1 86.1 20.3 25.1 20.4 20.4 20.4 60.5 23.3 25.5 15.1 14.4 12.6 2.7 2.3 20.8 10.9 Sanofindia Buy 5721 7000 22 141.7 165.5 19.3 9.8 16.7 19.2 34.6 20.0 5.4 17.2 18.5 Shilpa Medicare Buy 465 540 16 13.5 18.7 9.8 43.6 54.0 16.1 14.0 44.0 16.0 16.3 13.1 14.3 Strides Pharma Buy 465 540 16 13.5 17.4 18.5 24.0 18.0 40.0 16.1 15.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 16.1 <td< td=""><td>Granules</td><td>Buy</td><td>114</td><td>140</td><td>23</td><td>5.6</td><td>8.9</td><td>10.4</td><td>-23.2</td><td>60.1</td><td>16.5</td><td>12.8</td><td>11.0</td><td>2.0</td><td>1.8</td><td>16.3</td><td>17.0</td></td<>	Granules	Buy	114	140	23	5.6	8.9	10.4	-23.2	60.1	16.5	12.8	11.0	2.0	1.8	16.3	17.0
Jubilant Life Buy 872 1050 20 45.6 60.4 69.5 23.3 25.5 15.1 14.4 12.6 2.7 2.3 20.8 19.9 Lupin Buy 785 1000 27 32.0 25.9 38.3 43.5 18.0 47.8 19.0 5.9 5.4 17.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 19.2 34.6 24.2 34.6 24.2 18.8 24.7 18.0 16.0 12.4 14.2 14.8 44.7 18.0 16.0 12.4 14.8 24.2 34.6 28.6 24.2 38.4 24.8 35.8 30.0 13.1 14.9 Torrent Pharma Neutral 151 155 3 23.9 27.1 23.6 16.7 14.9 14.0 14.9 14.0 14.9 <td< td=""><td>GSK Pharma</td><td>Neutral</td><td>1299</td><td>1330</td><td>2</td><td>19.7</td><td>24.0</td><td>29.1</td><td>14.4</td><td>22.1</td><td>21.4</td><td>54.1</td><td>44.6</td><td>10.4</td><td>9.7</td><td>19.2</td><td>21.7</td></td<>	GSK Pharma	Neutral	1299	1330	2	19.7	24.0	29.1	14.4	22.1	21.4	54.1	44.6	10.4	9.7	19.2	21.7
LupinBuy78510002732.025.938.3-43.5-18.947.832.520.02.72.58.511.9Sanofi IndiaBuy5721700022141.7165.5197.39.816.712.854.024.054.024.05.05.417.218.5Shilpa MedicareBuy3674803112.815.223.4-0.718.354.024.015.015.853.3Sun PharmaBuy4655401613.516.723.2-85.5-26.69.340.64.018.01.613.515.724.854.930.013.11.71.518.314.9InfrastructureAgeregate17.717.5288.410.612.434.625.616.712.911.11.71.513.416.6RB InfraNeutral151155323.927.123.517.513.613.45.66.40.80.714.815.6SadbhavBuy26626812.913.513.417.55.21.1.118.71.513.41.6Ageregate12.914.414.461.825.41.0.41.91.41.210.31.6LagingeningBuy51.461.41917.412.713.513.417	IPCA Labs	Buy	886	970	9	19.0	35.3	42.5	18.1	86.1	20.3	25.1	20.9	3.6	3.1	15.4	16.1
Sanofi IndiaBuy5721700022141.7165.5197.39.816.719.234.629.05.95.417.218.5Shipa MedicareBuy3674803112.815.223.40.718.354.024.215.72.42.110.513.3Strides PharmaBuy4385903511.39.824.365.1-13.1148.044.718.01.61.53.58.3Storides PharmaBuy4365901151.615.72.42.88.72.43.82.7.82.02.85.116.419.9Aggregate	Jubilant Life	Buy	872	1050	20	45.6	60.4	69.5	23.3	32.5	15.1	14.4	12.6	2.7	2.3	20.8	19.9
Shilpa Medicar Buy 367 480 31 12.8 15.2 23.4 -0.7 18.3 54.0 24.2 15.7 2.4 2.1 10.5 14.3 Strides Pharma Buy 438 590 35 11.3 9.6 2.3. -68.1 -13.1 14.80 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 44.7 18.0 16.4 19.9 Aggregate 15.8 16.0 11.1 15.7 2.8 8.4 10.6 12.4 34.6 25.6 16.7 12.9 11.1 1.7 1.5 13.3 14.0 Stroka Buildcon Buy 137 175 2.8 8.4 10.6 12.4 14.6 14.8 13.6 14.0 14.0 14.0 14.0 14.0 14.0 14.0 14.0 14.0	Lupin	Buy	785	1000	27	32.0	25.9	38.3	-43.5	-18.9	47.8	32.5	22.0	2.7	2.5	8.5	11.9
Strides PharmaBuy4385903511.39.824.365.11.3.1148.044.718.01.61.53.58.3Sun PharmaBuy4655401613.516.723.248.524.238.827.820.02.82.510.313.1Torrent PharmaNeutral185816001153.748.768.52.29.340.638.127.12.85.116.419.9Aggregat	Sanofi India	Buy	5721	7000	22	141.7	165.5	197.3	9.8	16.7	19.2	34.6	29.0	5.9	5.4	17.2	18.5
Sun PharmaBuy4655401613.516.723.248.524.238.827.820.02.82.510.313.1Torrert PharmaNeutral18581660-1153.748.768.5-2.69.340.638.127.15.85.116.419.9AggregateInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructureInfrastructure <td>Shilpa Medicare</td> <td>Buy</td> <td>367</td> <td>480</td> <td>31</td> <td>12.8</td> <td>15.2</td> <td>23.4</td> <td>-0.7</td> <td>18.3</td> <td>54.0</td> <td>24.2</td> <td>15.7</td> <td>2.4</td> <td>2.1</td> <td>10.5</td> <td>14.3</td>	Shilpa Medicare	Buy	367	480	31	12.8	15.2	23.4	-0.7	18.3	54.0	24.2	15.7	2.4	2.1	10.5	14.3
Torrent Pharma Neutral 1858 1660 -11 53.7 48.7 68.5 -2.6 9.3 40.6 38.1 27.1 5.8 5.1 16.4 19.9 Aggregate	Strides Pharma	Buy	438	590	35	11.3	9.8	24.3	-65.1	-13.1	148.0	44.7	18.0	1.6	1.5	3.5	8.3
Aggregate -19.3 15.3 29.3 26.4 20.4 3.5 3.0 13.1 14.9 Infrastructure Ashoka Buildcon Buy 137 175 28 8.4 10.6 12.4 34.6 25.6 16.7 12.9 11.1 1.7.7 1.5. 14.3 14.6 IRB Infra Neutral 151 155 3 23.9 27.1 23.5 17.5 13.6 -13.4 5.6 6.4 0.8 0.7 14.8 11.5 KNR Buy 256 260 2 19.4 14.4 14.4 61.8 -25.4 -0.4 17.7 17.8 2.7 2.3 16.2 14.0 Sadbhav Engineering Buy 246 265 8 12.9 13.5 13.4 17.5 5.2 -1.1 18.2 18.4 2.0 1.9 11.8 10.5 Aggregate 10.2 10.7 1.4 1.2 10.3 10.7 Concor Buy 514 614 19 17.4 19.7	Sun Pharma	Buy	465	540	16	13.5	16.7	23.2	-48.5	24.2	38.8	27.8	20.0	2.8	2.5	10.3	13.1
Ashoka Buildcon Buy 137 175 28 8.4 10.6 12.9 11.1 1.7 1.6.7 12.9 11.1 1.7 1.6.7 12.9 11.1 1.7 1.6.7 12.9 11.1 1.7 1.6.7 12.9 1.1 1.7 1.6.7 12.9 1.1.1 1.7 1.1.1 1.7 1.2.9 1.1.1 1.7 1.2.9 1.1.1 1.7 1.2.8 1.1.1 1.7 1.2.9 1.1.1 1.8.7 1.1.1 1.8.7 1.1.1 1.8.2 1.8.4 1.0.2 1.0.7 1.4.4 1.6.2 1.8.7 1.1.1 1.8.7 1.1.1 1.8.2 1.1.1 1.1.6																	



Click excel icon for detailed valuation guide

1

		СМР	ТР	% Upside		EPS (INF	2)	FDG	Gr. Yo	V (%)	D/F	(x)	D/P	; (x)	ROE	: (%)
Company	Reco	(INR)	(INR)	Downside		•	57 FY20E		FY19E	FY20E	•				FY19E	<u> </u>
SAIL	Neutral	52	52	1	0.3	6.3	6.1	LP	2,330	-3.1	8.2	8.5	0.5	0.5	6.8	6.2
Rain Industries	Buy	105	123	17	23.7	20.4	13.7	238.1	-14.0	-32.8	5.2	7.7	0.8	0.7	16.0	9.9
Vedanta	, Sell	175	162	-8	20.4	13.8	21.5	34.6	-32.2	55.4	12.7	8.2	1.1	1.0	8.3	12.8
Tata Steel	Sell	516	370	-28	69.5	88.7	72.0	83.3	27.6	-18.9	5.8	7.2	0.9	1.1	17.3	14.1
Aggregate								74.2	17.3	-3.0	9.5	9.8	1.2	1.2	12.8	12.0
Oil & Gas																
Aegis Logistics	Buy	204	277	36	5.9	6.6	9.7	64.5	11.1	47.3	31.0	21.1	5.0	4.2	17.0	21.7
BPCL	Buy	397	398	0	49.8	34.8	41.6	3.0	-30.0	19.5	11.4	9.5	1.9	1.7	17.8	19.2
GAIL	Neutral	359	346	-4	20.4	29.4	29.9	20.5	44.3	1.5	12.2	12.0	1.8	1.6	15.7	14.4
Gujarat Gas	Buy	150	165	10	4.2	5.9	6.4	32.7	40.3	7.7	25.2	23.4	4.8	4.1	20.4	19.0
Gujarat St. Pet.	Buy	181	209	16	11.9	15.2	14.8	34.6	28.3	-2.4	11.9	12.2	1.8	1.6	15.8	13.6
HPCL	Neutral	276	231	-16	47.4	36.6	42.5	-12.4	-22.7	16.0	7.6	6.5	1.5	1.3	20.6	21.2
IOC	Buy	157	183	17	23.9	13.8	16.3	11.0	-42.3	18.1	11.4	9.6	1.2	1.2	11.2	12.5
IGL	Buy	290	389	34	9.4	10.9	12.7	9.2	15.7	16.7	26.6	22.8	4.9	4.3	20.0	20.1
Mahanagar Gas	Buy	936	1300	39	48.4	57.1	59.8	21.5	18.1	4.7	16.4	15.6	3.8	3.4	25.0	22.9
MRPL	Buy	73	77	5	12.8	1.4	10.6	-13.6	-89.2	674.2	53.4	6.9	1.1	1.0	2.2	15.6
Oil India	, Buy	179	239	34	23.6	29.3	30.7	-1.2	24.2	4.9	6.1	5.8	0.7	0.6	11.5	11.4
ONGC	Buy	156	182	17	20.2	26.9	30.3	-9.9	33.5	12.5	5.8	5.1	0.9	0.8	16.1	16.4
PLNG	Buy	236	311	32	13.9	15.0	17.4	21.8	8.6	15.4	15.7	13.6	3.3	3.0	22.1	23.3
Reliance Ind.	, Buy	1323	1426	8	60.9	65.0	74.0	20.7	6.6	13.9	20.4	17.9	2.4	2.1	12.4	12.6
Aggregate								5.5	-1.5	14.7	12.8	11.1	1.7	1.5	13.3	13.9
Retail																
Jubilant Food	Neutral	1343	1300	-3	14.9	24.8	28.1	180.4	67.1	13.1	54.0	47.8	15.1	12.8	27.9	26.7
Titan Co.	Buy	1095	1180	8	12.6	16.4	20.8	39.9	29.5	27.1	67.0	52.7	19.0	16.4	28.5	33.4
Aggregate								51.1	35.1	24.5	64.0	51.4	18.1	15.5	28.3	30.2
Technology																
Cyient	Neutral	669	720	8	38.2	39.4	48.8	24.8	3.0	23.8	17.0	13.7	2.9	2.6	17.0	18.9
HCL Tech.	Neutral	1028	1105	7	62.6	74.3	83.0	4.5	18.8	11.7	13.8	12.4	3.3	3.0	25.9	25.4
Hexaware	Neutral	341	365	7	16.6	19.3	21.5	21.2	16.5	11.3	17.7	15.9	4.3	3.8	26.5	25.5
Infosys	Buy	719	865	20	32.4	36.4	39.2	3.1	12.4	7.7	19.8	18.4	5.0	5.0	25.6	27.4
L & T Infotech	Neutral	1628	1950	20	66.3	90.9	94.4	19.6	37.0	3.9	17.9	17.2	5.6	4.5	35.6	29.0
Mindtree	Buy	946	1000	6	34.4	47.3	53.0	38.0	37.7	11.9	20.0	17.9	4.9	4.2	25.5	25.1
Mphasis	Neutral	985	1050	7	44.0	58.4	62.7	13.2	32.6	7.4	16.9	15.7	5.4	4.5	24.3	31.6
NIIT Tech	Neutral	1336	1400	5	45.6	69.5	82.2	19.8	52.6	18.1	19.2	16.3	4.2	3.6	23.1	24.1
Persistent Sys	Buy	666	800	20	40.4	46.8	55.8	7.2	16.0	19.1	14.2	11.9	2.2	2.1	16.7	17.8
Tata Elxsi	Buy	979	1050	7	38.7	45.6	50.4	37.7	17.8	10.5	21.5	19.4	6.6	4.4	34.1	27.2
TCS	Neutral	2040	2000	-2	66.0	82.8	90.5	-1.0	25.4	9.3	24.6	22.5	9.1	8.6	36.6	39.3
Tech Mah	Buy	800	940	18	42.7	49.1	55.0	33.6	15.0	11.9	16.3	14.5	3.5	3.3	22.8	23.8
Wipro	Neutral	263	282	7	13.4	15.2	17.7	7.7	13.2	16.4	17.3	14.9	2.7	2.6	17.7	17.9
Zensar Tech	Buy	230	260	13	10.6	14.0	15.5	1.3	32.8	10.6	16.4	14.8	2.7	2.4	17.9	17.2
Aggregate								5.2	14.8	8.6	20.5	18.9	5.5	5.2	26.7	27.4
Telecom																
Bharti Airtel	Buy	337	380	13	3.5	-7.6	-5.6	-68.6	PL	Loss	NM	NM	2.3	2.4	-4.7	-3.9
Bharti Infratel	Neutral	314	290	-8	13.6	14.0	13.4	-8.1	2.5	-4.4	22.4	23.5	3.5	3.7	15.5	15.3
Vodafone Idea	Buy	34	40	18	-9.6	-18.6	-18.8	Loss	Loss	Loss	NM	NM	0.5	0.7	-37.0	-31.5
Tata Comm	, Buy	609	630	4	1.2	1.3	11.2	-89.0	15.9	732.3	452.2	54.3	25.2	17.2	6.5	37.6
Aggregate								PL	Loss	Loss	-15	-15.3	1.8	2.1	-12.1	-13.5
Utiltites																
Coal India	Buy	245	281	15	19.2	27.4	29.0	26.3	43.0	6.0	8.9	8.4	7.4	6.8	82.5	80.4
CESC	Buy	721	800	11	62.1	75.4	80.0	54.6	21.5	6.0	9.6	9.0	1.1	1.0	11.4	11.2
JSW Energy	Neutral	67	73	8	3.0	3.8	4.6	-21.2	24.5	21.8	17.9	14.7	1.0	0.9	5.5	6.5
NHPC	Buy	25	31	23	2.4	2.2	2.6	-17.3	-9.9	20.4	11.4	9.5	0.8	0.8	7.4	8.7
NTPC	Buy	158	197	25	10.7	13.3	16.6	-10.9	25.1	24.2	11.8	9.5	1.2	1.1	10.3	12.0
Power Grid	Buy	192	232	21	16.5	18.3	20.8	16.1	10.4	13.9	10.5	9.3	1.7	1.5	16.7	17.1
Tata Power	Neutral	74	69	-6	5.3	2.5	6.6	3.5	-52.8	163.4	29.2	11.1	1.2	1.1	4.3	10.3
		-		-		-						-	-	-	-	



Click excel icon for detailed valuation guide

1



		СМР	ТР	% Upside		EPS (INF	۲)	EPS	Gr. Yo	Y (%)	P/E	(x)	P/E	3 (x)	ROE	E (%)
Company	Reco	(INR)	(INR)	Downside	FY18	FY19E	FY20E	FY18	FY19E	FY20E	FY19E	FY20E	FY19E	FY20E	FY19E	FY20E
Aggregate								7.2	24.4	13.7	10.2	9.0	1.7	1.6	17.1	18.1
Others																
Avenue Supermarts	Sell	1478	1400	-5	12.9	15.5	21.4	68.4	19.7	38.6	95.6	69.0	16.4	13.2	18.7	21.2
Brigade Enterpr.	Buy	228	283	24	10.8	16.7	16.5	-4.0	54.2	-0.9	13.7	13.8	1.3	1.2	9.5	8.8
BSE	Buy	616	750	22	43.5	34.7	40.1	6.0	-20.2	15.6	17.8	15.4	0.9	0.9	4.9	5.6
Castrol India	Buy	164	215	31	7.0	7.2	7.2	2.9	2.4	1.0	22.9	22.7	13.9	12.6	64.8	58.5
Coromandel Intl	Buy	480	571	19	22.7	23.9	28.5	38.8	5.4	19.0	20.1	16.9	3.9	3.4	20.9	21.6
Delta Corp	Buy	246	312	27	5.8	7.0	9.0	89.4	21.2	29.0	35.1	27.2	3.8	3.3	11.0	12.9
Indian Hotels	Buy	149	189	27	0.7	2.4	3.1	LP	270.2	26.8	60.9	48.0	4.0	3.7	6.8	8.0
Interglobe	Neutral	1297	1041	-20	58.3	-5.7	54.5	35.1	PL	LP	NM	23.8	7.3	6.9	-3.2	29.8
Info Edge	Neutral	1870	1670	-11	14.9	24.4	30.9	-3.3	64.0	26.7	76.6	60.5	9.9	8.8	14.3	15.5
Kaveri Seed	Buy	439	582	33	32.0	32.9	36.9	67.8	2.7	12.2	13.3	11.9	2.6	2.4	20.6	21.2
МСХ	Buy	785	900	15	21.2	23.1	30.1	-14.6	8.9	30.2	34.0	26.1	3.3	3.1	9.0	12.1
Navneet Education	Buy	109	159	46	5.5	8.3	9.8	-25.4	53.0	17.7	13.0	11.1	3.2	2.8	24.8	26.7
Oberoi Realty	Buy	487	560	15	12.6	22.2	34.5	21.2	75.9	55.6	21.9	14.1	2.2	2.0	11.5	14.8
Phoenix Mills	Buy	677	708	5	15.8	16.9	21.8	44.2	6.5	29.3	40.2	31.1	3.0	2.8	8.2	9.4
Quess Corp	Neutral	794	730	-8	21.8	17.8	32.0	115.7	-18.4	79.8	44.6	24.8	3.3	2.8	10.0	15.8
PI Inds.	Buy	1010	1023	1	26.7	28.5	35.4	-20.2	6.8	24.4	35.5	28.5	6.3	5.4	19.0	20.4
Piramal Enterp.	Buy	2643	2775	5	77.8	78.0	126.1	7.2	0.2	61.7	33.9	21.0	1.9	1.8	5.8	8.9
SRF	Buy	2412	2636	9	77.9	106.6	134.4	-11.5	36.8	26.0	22.6	17.9	3.5	3.0	16.4	18.0
S H Kelkar	Buy	151	207	38	7.1	6.4	7.6	-2.2	-10.3	19.5	23.7	19.8	2.4	2.2	10.3	11.4
Tata Chemicals	Buy	584	771	32	48.2	41.2	47.3	39.7	-14.5	14.7	14.2	12.4	1.3	1.2	9.2	9.8
Team Lease Serv.	Buy	2787	3400	22	43.0	61.0	89.9	28.0	41.8	47.3	45.7	31.0	8.5	6.7	20.6	24.2
Trident	Buy	68	94	38	5.3	8.5	9.7	-21.8	60.9	13.7	8.0	7.1	1.1	1.0	13.8	14.4
UPL	Buy	922	1035	12	43.8	45.2	47.8	4.8	3.3	5.7	20.4	19.3	4.3	3.6	23.1	20.6



MOSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Automobiles			
Amara Raja	-0.2	0.9	-6.0
Ashok Ley.	0.1	17.2	-37.7
Bajaj Auto	0.4	7.2	2.5
Bharat Forge	0.8	14.1	-27.9
Bosch	-0.8	1.8	2.3
CEAT	1.2	9.3	-27.4
Eicher Mot.	0.0	12.0	-21.0
Endurance Tech.	-0.1	-7.6	-8.0
Escorts	-0.2	25.3	-5.6
Exide Ind	0.0	11.1	5.5
Hero Moto	-0.6	1.4	-24.8
M&M	1.1	10.4	-5.7
Maruti Suzuki	0.1	2.4	-19.7
Motherson Sumi	1.2	26.5	-21.1
Tata Motors	0.3	11.9	-49.0
TVS Motor	0.2	2.8	-23.4
Banks - Private			-
AU Small Fin. Bank	3.9	6.0	2.3
Axis Bank	-0.6	7.2	39.1
DCB Bank	0.6	16.7	22.5
Equitas Hold.	-0.5	18.2	-7.2
Federal Bank	1.3	13.8	-2.6
HDFC Bank	1.3	7.2	19.8
ICICI Bank	2.0	15.7	31.3
IndusInd	1.1	12.6	-2.4
Kotak Mah. Bk	4.3	3.2	21.9
RBL Bank	1.6	18.1	35.9
South Indian	2.8	20.2	-39.1
Yes Bank	-1.9	12.0	-39.1
Banks - PSU	-1.9	12.0	-21.0
BOB	1.2	16.8	-17.9
BOI	0.6	16.0	-17.9
Canara	1.0	23.0	0.2
Indian Bk	-0.3	25.4	-12.5
PNB			
	1.8	22.8	-12.8
SBI	2.2	13.2	17.2
Union Bk	0.2	20.9	-18.1
NBFCs	2.2	22.0	24.2
Aditya Birla Cap	3.2	23.8	-34.2
Bajaj Fin.	1.8	11.8	65.7
Cholaman.Inv.&Fn	1.9	16.9	-6.2
HDFC	1.0	5.4	8.0
HDFC Life Insur.	0.9	3.3	-17.4
Indiabulls Hsg	-0.3	9.6	-43.4
L&T Fin.Holdings	2.3	16.7	-9.5
LIC Hsg Fin	-0.4	15.8	-2.5
M&M Fin.	1.9	14.8	-0.2
Muthoot Fin	0.4	15.4	50.5
MAS Financial Serv.	5.6	8.4	-1.4
ICICI Pru Life	1.1	12.4	-11.1
PNB Housing	-1.5	-2.2	-21.3
Repco Home	0.2	33.9	-21.1
Shriram City Union	0.8	15.2	-15.6
Shriram Trans.	1.7	26.3	-13.1
Capital Goods			
ABB	-0.3	4.7	-5.1
Bharat Elec.	1.8	25.8	-37.5

Company	1 Day (%)	1M (%)	12M (%)
BHEL	0.5	11.1	-22.1
Blue Star	-1.4	14.4	-16.9
CG Cons. Elec.	0.4	12.9	2.4
Cummins	-0.1	8.1	-5.7
Engineers India	-0.3	5.0	-31.4
GE T&D	-1.6	3.1	-24.2
Havells	-0.2	8.3	43.3
K E C Intl	1.2	22.1	-23.8
L&T	1.3	12.4	7.9
Siemens	-0.3	7.6	-8.8
Solar Ind	0.0	7.8	3.2
Thermax	-1.4	1.7	-13.7
Va Tech Wab.	-1.1	12.3	-36.3
Voltas	-0.5	14.8	-6.4
Cement		-	
Ambuja Cem.	0.3	10.0	-6.9
ACC	-0.5	13.3	-4.4
Birla Corp.	0.1	18.9	-32.7
Grasim Inds.	-0.4	17.4	-25.2
India Cem	-3.9	16.2	-35.2
J K Cements	-0.1	15.7	-20.2
JK Lakshmi Ce	0.5	14.3	-19.8
Ramco Cem	-1.7	15.6	-5.7
Orient Cem	-0.9	28.0	-40.0
Prism Johnson	-5.9	30.5	-21.4
Sanghi Inds.	1.1	15.0	-51.2
Shree Cem	-0.6	12.5	4.6
Ultratech	-1.2	13.8	-6.1
Consumer	1.2	15.0	0.1
Asian Paints	-0.1	2.7	23.4
Britannia	-2.5	7.3	26.5
Colgate	-0.6	3.2	22.0
Dabur	-3.1	-2.2	30.9
Emami	-1.7	8.7	-25.1
Future Consumer	-2.7	5.3	-24.8
Godrej Cons.	-1.5	6.3	-1.3
GSK Cons.	-1.6	-4.8	8.3
HUL	-2.2	-4.2	30.9
ITC	-1.5	4.1	9.6
Jyothy Lab	-1.3	4.4	3.2
Marico	-2.0	0.1	12.7
Nestle	-3.8	-2.4	33.8
Page Inds	-0.3	7.4	11.5
Parag Milk	-0.5	25.6	-8.7
Pidilite Ind.	-0.3	6.7	28.2
P&G Hygiene	0.1	2.8	8.2
United Brew	0.4	3.3	35.0
United Spirits	-0.6	14.7	-8.7
Healthcare	0.0		5.7
Alembic Phar	-0.3	1.5	1.0
Alkem Lab	1.9	-3.0	-20.1
Ajanta Pharma	-1.2	4.3	-26.3
Aurobindo	-1.2	6.7	34.6
Biocon	0.7	1.2	3.9
Cadila	3.6	8.9	-11.2
Cipla Divis Lab	-0.3	-1.6	-6.9
Divis Lab Dr Reddy's	0.8	5.6	57.3
	0.2	4.0	21.8



MOSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Glenmark	1.5	12.3	16.2
Granules	1.2	31.9	1.3
GSK Pharma	-0.9	-5.4	13.4
IPCA Labs	-0.9	14.3	32.1
Jubilant Life	1.5	14.5	2.4
	2.4	19.5	1.1
Lupin Sanofi India	-0.1	-8.0	1.1
	0.2	-8.0	
Shilpa Medicare Strides Pharma	-2.5		-20.6
		<u>8.8</u> 9.7	-36.5
Sun Pharma	-0.5		-10.1
Torrent Pharma	1.2	4.6	45.2
Infrastructure	4.2	24.0	10.2
Ashoka Buildcon	-1.3	21.9	-10.2
IRB Infra.Devl.	-0.6	24.8	-30.8
KNR Construct.	-0.6	23.5	-13.3
Sadbhav Engg.	-4.1	50.7	-35.3
Logistics			
Allcargo Logistics	-0.9	16.8	-25.8
Concor	1.4	5.0	3.6
Media			
D B Corp	-0.8	11.8	-39.0
Ent.Network	0.2	1.0	-25.8
Jagran Prak.	-1.2	19.5	-31.7
Music Broadcast	1.7	13.4	-16.0
PVR	0.0	9.6	24.4
Sun TV	0.7	12.8	-32.8
Zee Ent.	0.9	5.8	-20.3
Metals			
Hindalco	-1.1	6.7	-11.5
Hind. Zinc	0.2	10.9	-13.7
JSPL	0.5	19.8	-28.1
JSW Steel	0.5	7.9	-2.4
Nalco	3.6	11.9	-17.2
NMDC	0.1	24.8	-8.0
Rain Industries	-4.6	15.6	-73.0
SAIL	-2.2	14.9	-31.5
Vedanta	0.9	18.9	-44.6
Tata Steel	-0.4	10.3	-15.7
Oil & Gas			
Aegis Logistics	-0.5	15.6	-17.1
BPCL	1.6	21.2	-14.3
GAIL	1.2	12.8	6.2
Gujarat Gas	-3.4	25.5	-11.5
Gujarat St. Pet.	0.4	13.2	-5.0
HPCL	3.4	27.5	-25.6
IOC	3.5	27.5	-23.0
IGL	-0.4	24.9	-18.4
Mahanagar Gas	0.8	8.6	-2.8
Mananagar Gas MRPL	0.0	15.5	-9.4 -37.7
Oil India	0.1	3.9	-20.5
ONGC	2.8	15.2	-14.2
PLNG	-0.5	10.1	-0.3
Reliance Ind.	-1.4	6.4	45.0
Retail			
Jubilant Food	0.9	3.3	25.2
Titan Co.	1.0	5.4	25.6


Company	1 Day (%)	1M (%)	12M (%)
Technology			
Cyient	-0.8	12.0	6.3
HCL Tech.	2.1	-2.8	7.4
Hexaware	1.3	-5.0	-10.4
Infosys	1.5	-3.1	21.6
L&T Infotech	-1.4	-8.0	22.1
Mindtree	-0.5	5.8	12.2
Mphasis	2.8	-6.5	11.8
NIIT Tech	1.2	5.6	35.2
Persistent Sys	-1.5	2.5	-20.9
Tata Elxsi	3.1	13.8	-5.8
TCS	2.6	0.5	42.2
Tech Mah	1.4	-0.1	26.5
	2.3	-0.1	19.4
Wipro Zancar Tach	-		24.2
Zensar Tech	6.5	8.2	24.2
Telecom Rharti Airtal	1 7	10 7	10.0
Bharti Airtel	-1.7	10.7	-19.9
Bharti Infratel	-0.1	2.2	-7.2
Idea Cellular	0.3	12.6	-57.7
Tata Comm	0.1	22.7	-4.6
Utiltites			
Coal India	0.5	11.7	-17.2
CESC	-0.7	6.3	-3.8
JSW Energy	0.2	3.7	-14.5
NHPC Ltd	1.4	5.7	-6.2
NTPC	2.5	15.7	-7.2
Power Grid	2.6	6.0	-1.2
Tata Power	1.0	6.5	-8.0
Others			
Avenue Super.	0.7	0.7	8.9
Brigade Enterpr.	-0.7	16.7	-17.0
BSE	-0.2	9.7	-21.2
Castrol India	-1.5	11.3	-20.1
Coromandel Intl	-0.1	7.9	-9.1
Delta Corp	-1.8	10.8	-20.5
Indian Hotels	-0.8	8.9	11.7
Interglobe	-0.2	13.0	2.6
Info Edge	-1.3	10.6	48.2
Kaveri Seed	0.2	-8.8	-11.2
MCX	0.6	17.6	-4.8
Navneet Educat.	-1.3	4.6	-21.3
Oberoi Realty	1.5	4.3	-10.2
Phoenix Mills	2.8	13.1	9.0
PI Inds.	-0.1	13.2	17.5
Piramal Enterp.	-0.4	22.3	7.8
Quess Corp	1.8	23.3	-21.9
SRF	2.4	9.7	28.4
S H Kelkar	0.0	-2.8	-43.6
Tata Chemicals	1.3	5.4	-14.4
Team Lease Serv.	-3.1	-2.8	34.0
Trident	-3.5	11.7	-0.9
UPL	2.0		27.7
	2.0	12.9	21.1

THEMATIC/STRATEGY RESEARCH GALLERY
























REPORT GALLERY

RECENT INITIATING COVERAGE REPORTS











Valual Purentys: Research Analyst (Yrshal Purentys@MottaWorked.com), +51.22 (980-451) Krotsens Landbaroothy, - Research Analyst (Yrshan Sumbaroothy@MottaWorked.com), 491.22 (982-543) Investors are advised to refer through Important disclosures made at the last page of the Research Report. Mode Youri answer to invalid a view monitoriated analysis, Saming and Tamas Harm, Sami at 15 April




Turbar Menufaces - Research analysis Turbar Neurolawar (Michael Const. and - HL 11 COR 1018 Eagle Tomorations - Research analysis Transform (West Neuronal West Neuronal) - et al. 12 Keil 2011 Turbaren and advances for the Research Responses of Autochanaes manks or the Neuronae Neuronae Neuronae Neurona Neuronae Neuro



The Specialist





The Giant Kelp

Abhain Dahinale - Rearach Analysi (Ashain Dahinele Brootianis et ann), 411 22 3800 4800 Taeannach Bhorban - Reisean Analysi (Swarinach Bhorband) Abhorbanding (ann), 411 22 4123 1329 Raveston ar an an adhaidh to freit fhrosgin Inspirated Galances maket at the taet page of the Research Report. Method Dave march is walket an anon-minimum an instrumed Spiran, Bhorban Boren, Horar and Mit Capitel



Senar Kanon Remote Kanjan (Senar Kano Demotrational and 4012 403 104 Remote Kanjan Chann Mad (Senar Kano Demotrational and 1912 402)/004 Mediate (State Verbater) demotrational and Westelless are enfolded to refer through important disclosurers made at Ute Into page of the Research Negoric Mediatricus many section are methodic and substantiant disclosurers (Senar 2014 Department).

DIFFERENTIATED PRODUCT GALLERY



*Arcting is under of president ()

Store ()

S

Research & Quant Team (Deven@MotilalOswal.com); +91 22 6129 1575

A strain of the strain of the

Mid-caps underperform large-caps
Fils buying after three months of consecutive selling



Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Securities Ltd. (MOSL*) is a SEBI Registered Research Analyst having registration no. INH000000412. MOSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOSL is a subsidiary company of Motilal Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on <u>www.motilaloswal.com</u>. MOSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Society Services. A National Commodity & Derivatives Exchange Ltd. (NOFEX). MOESL is a subsidiary company of Motilal Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on <u>www.motilaloswal.com</u>. MOSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Society Services. Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products. Details of associate entities of Motilal Oswal Securities Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOSL, it's associates, Research Analyst or their relative may have any financial interest in the subject company. MOSL and/or its associates and/or Research Analyst may have actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. MOSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. MOSL and/or its associates may have received any compensation from the subject company in the past 12 months.

In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, MOSL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report,

- b)
- Interleged of Contraling to December of Section and Se c) d)
- Subject Company may have been a client of MOSL or its associates during twelve months preceding the date of distribution of the research report.

MOSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. To enhance transparency, MOSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Terms & Conditions:

This report has been prepared by MOSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement Analyst ownership of the stock

Companies where there is interest

No A graph of daily closing pictures of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>, Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INHOD0000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report is Intended for distribution only to "Professional Investors" as defined in Part Lof Schedule 1 to SFO. Any investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from the securities of the securities registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Molifal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the "34 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors: a defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relide to by persons who are not major institutional investors: Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. Bused of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motial Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd (*MOCMSPL*) (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such the securities and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior within a formation herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or self or subscribe for securities or there in any torm investment document or solicitation of any torm securities or there in any torm investment document or solicitation of any torm securities or there in any torm investment document or solicitation of any torm securities or there in any torm investment or strategy is suitable or appropriate to your specific circumstances. The securities document or solicitation of any not be suitable for all investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities document or solicitation of any not be suitable for all investment. Legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities or there in substitution for the exercise of independent judgment by any recipient. Each recipient of this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOSL. The views expressed are those of the analyst, and into account before interpreting the document. Ihis report has been prepared on the basis of intormation that is already available in publicly accessible media or developed through analysis of MOSL. The views expressed are those of the analysis, and the Company may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or epublished, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or neitily who is a clitzen or resident of or located in any locailty, stale, country or other jurisdiction, where such distribution, availability or use would be contrary to law, regulation or which would subject MOSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 3080 1000. Compliance Officer: Neeraj Agarwal, Email Id: na@moilialoswal.com, Contact No: 022-30801085

Registration details of group entities: MOSL: SEBI Registration: INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412. AMFI: ARN 17397. Investment Adviser: INÃ000007100.Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP00000670) offers PMS and Mutual Funds products. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP00000409) offers wealth management solutions. *Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. offers Real Estate products. * Motilal Oswal Private Equity Investment Advisors Pvt. Ltd. offers Private Equity products

*MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench. The existing registration no(s) of MOSL would be used until receipt of new MOFSL registration numbers.